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ABSTRACT
Endocannabinoid modulation of secretory and inflammatory causes of gastric
pathology
Molly S. Crowe
Non-steroidal anti-inflammatory drugs (NSAIDs) are common analgesic drugs that also cause
well-known, negative gastrointestinal (GI) side effects. The specific physiological mechanism(s)
of NSAID-induced GI damage are unknown, and are likely due to multiple causes. The most
studied components include: increased gastric acid secretions, inflammation of the gastric
epithelium, and increased gastric motility. Currently, proton pump inhibitor (PPI) antacids are used
by chronic NSAID users, with the expectation that decreasing gastric acid output will reduce
gastric epithelial irritation. However, PPIs are associated with side effects like infection, gastric
polyps, and dementia. Therefore, new gastroprotective treatments that prevent NSAID-induced
gastropathy are needed. The endocannabinoid system has several possible targets to reduce
NSAID-induced ulcers, including the endocannabinoid 2-AG (2-arachidonoylglycerol), and the
primary enzyme that metabolizes 2-AG, monoacylglycerol lipase (MAGL). Blocking the MAGL
enzyme increases stomach levels of 2-AG and reduces NSAID-induced ulcers in male mice. The
present project was designed to determine which ulcerogenic effects of the NSAID diclofenac are
reversed by MAGL inhibition. We hypothesized that MAGL inhibition would reverse the
following effects of diclofenac: (1) increased gastric acid secretion; (2) increased gastric
inflammation; and (3) increased gastric motility. Diclofenac induced gastric hemorrhages to a
similar extent in both male and female mice. Diclofenac dose-dependently increased neutrophil
infiltration in both male and female mice, indicating that diclofenac induces a cell-mediated
inflammatory response. Gastric hemorrhage severity correlated with myeloperoxidase levels, an
objective measure of immune cell infiltration, indicating its use as a potential biomarker of gastric
damage. Diclofenac significantly increased inflammatory cytokines in male mice, whereas
administration of JZL184, a MAGL inhibitor, prior to diclofenac had no effect in male mice and
increased gastric inflammatory cytokine levels in female mice. Neither JZL184 nor diclofenac
produced any changes on gastric acid secretions when evaluated during the gastric hemorrhage
procedure. However, in the pentagastrin-stimulated acid model, JZL184 decreased gastric acid
secretions in both basal and stimulated conditions. As hypothesized, JZL184 decreased gastric
motility, although diclofenac, contrary to expectations, slowed gastric motility, indicating that
diclofenac-induced ulcers most likely do not occur through increased gastric motility, at least not
as measured in the present study. The present data indicate that MAGL inhibition may proffer
gastroprotection through modulating the secretory pathway of gastric hemorrhage. These data
underscore the importance of sampling multiple time points and using both sexes in research, in
addition to multiple mechanistic targets, and contribute to the basic understanding of NSAIDinduced gastric inflammation.
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Background
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid (aspirin),
are used world-wide and remain the most commonly used pharmaceutical therapies for pain
(Lanas, 2009). However, chronic pain can be resistant to NSAIDs, leading to more frequent
administration and increased dosages (Adams et al., 2006). Approximately 20% of all chronic
NSAID users develop band-like lesions (i.e. gastric hemorrhages) in the stomach or duodenum
that are, at some point, severe enough to require medical intervention (Wallace, 2001). The
severity of gastric hemorrhaging and other negative side effects of NSAIDs increase with age
and can be predicted to some degree by the patient’s individual medical history (Raffa, 2001).
For example, the incidence of NSAID-induced gastric hemorrhages can be as high as 45% in
arthritis patients (Laine et al., 1999). Proton pump inhibitors (PPI) are regularly co-prescribed to
prevent the ulcerogenic effect of NSAIDs by reducing gastric acid secretion (Mössner, 2016).
However, chronic PPI use is associated with negative side effects including gastric polyps,
tumors, infection, vitamin deficiencies, bone fractures, cancer, and dementia (Kuller, 2016;
Lodato et al., 2010; Mössner, 2016). The negative side effects of both NSAIDs and PPIs
emphasize the need for new gastroprotective therapeutics.
Gastric physiology
The gastrointestinal (GI) system is a continuous tube that is split into upper and lower
tracts. The upper GI includes the esophagus, stomach, and duodenum, whereas the lower GI is
composed of the small and large intestines (Gaskins, 1999). The main purpose of the GI system
is to digest food, extract nutrients, and expel waste (Ermund et al., 2013). The GI system is
composed of many different types of cells, enzymes, and microorganisms that are involved in the
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physiological actions of the GI. The GI contains an independent nervous system, the enteric
nervous system, which is known as “the brain of the gut” and can be influenced by the central
nervous system (CNS) (DiPatrizio, 2016; Ermund et al., 2013; Goyal & Hirano, 1996).
The enteric nervous system is responsible for many physiological processes of the
gastrointestinal system, such as motility, immune and inflammatory responses, secretion, and
microcirculation (Goyal & Hirano, 1996). The myenteric plexus and submucosal plexus are the
two main networks of afferent (sensory neurons) and efferent nerves (motor neurons) of the
enteric nervous system (Aviello, Romano, & Izzo, 2008). The myenteric plexus is involved in
gastrointestinal motility, whereas the submucosal plexus function is not completely understood,
but connects the mucosal layer of the stomach to deeper muscle layers (Aviello et al., 2008;
Costa, Brookes, & Hennig, 2000; Goyal & Hirano, 1996). The plexuses are composed of (1)
intrinsic sensory neurons that are activated by mechanical or chemical stimuli; (2) motor neurons
that cause contraction (i.e., excitatory) mediated by the excitatory neurotransmitter acetylcholine,
or relaxation (i.e., inhibitory), mediated predominantly via nitric oxide in the gastrointestinal
system; as well as (3) interneurons, which relay signals between the sensory and motor neurons
(Aviello et al., 2008; Sinn et al., 2010).
The enteric nervous system and the central nervous system communicate bi-directionally,
and while each nervous system functions independently, there are many connections between
them (DiPatrizio, 2016; Goyal & Hirano, 1996). The most notable connection is the vagus nerve,
also known as the pneumogastric nerve. The vagus nerve is the 10th cranial nerve (i.e., CN X)
and originates in the brain stem with peripheral nerve terminals innervating all layers of the
gastrointestinal system, and has the densest expression in the stomach (Berthoud, Carlson, &
Powley, 1991; McMenamin, Travagli, & Browning, 2016).
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The stomach is composed of multiple physical layers and is divided into three
topographical areas: the fundus, corpus, and antrum (Figure 1). Within each of these
topographical areas, the tissue is subdivided into four layers: mucosa, submucosa, muscularis
propria, and serosa (Figure 1). The surface layer of the stomach is the mucosa, which is lined
with epithelial cells. A mucosal gel barrier, made of mucus and bicarbonate, covers the
epithelium and provides a physical barrier between the epithelium and the contents of the
stomach. In addition, the mucosal barrier helps maintain a neutral pH microenvironment around
the epithelial cells, thereby protecting the cells from vast ranges of temperature and pH that
regularly occur in the stomach (Laine, Takeuchi, & Tarnawski, 2008). The epithelial cells are
folded into gastric pits that give the empty stomach its characteristic “ridged” appearance
(Dimaline & Varro, 2007; Schubert & Peura, 2008) (Figure 1). At the base of the gastric pits,
mucus and gastric acid are excreted by the cells of the oxyntic and pyloric glands (Dimaline &
Varro, 2007; Schubert, 2008; Schubert & Peura, 2008). The mucosa also contains a layer of
connective tissue and a thin layer of muscle. The second layer of the stomach is the submucosa,
which contains connective tissue, blood vessels, and nerves, and regulates peristalsis (i.e.,
rhythmic contraction and relaxation) of the smooth muscle (Laine et al., 2008). Adjacent to the
submucosa is the muscularis propria, a three-layer muscle structure that also contributes to
peristalsis of the stomach. The myenteric plexus is situated in this muscle layer. The serosa is the
outer most layer of the stomach and is a thin layer of epithelia cells that covers the stomach.
Prostaglandins regulate gastric function
In addition to the layers of mucosa and muscle that protect the stomach, prostaglandins
are a collection of signaling molecules that are essential for the defense systems in the stomach.
Prostaglandins are synthesized from arachidonic acid by cyclooxygenase (COX-1 and COX-2)
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enzyme activity and are produced throughout the body and modulate many physiological
processes (Fitzpatrick, 2004). COX-1 is constitutively expressed and produces prostaglandins
that provide homeostatic functions and regulate the gastric mucosa (Rouzer & Marnett, 2009),
whereas COX-2 is induced by tissue injury and produces prostaglandins involved in
inflammation (Viegas, Manso, Corvo, Marques, & Cabrita, 2011). Prostaglandins in the
gastrointestinal tract regulate and maintain the gastric mucosal tissue layers and gastric acid
secretions (Singh, 1998).
Prostaglandins of interest in the stomach include E2 (PGE2) and I2 (PGI2), the highest
expressed prostaglandins in the stomach, as well as prostaglandins F2α (PGF2α) and D2 (PGD2),
which are also detected, although at much lower concentrations (Wallace, 2008). Although not
much is known about the functions of PGF2α and PGD2 in gastropathy, metabolites of PGD2 and
PGF2α are thought to be anti-inflammatory (Motilva, Alarcón De La Lastra, Bruseghini, Manuel
Herrerias, & Sánchez-Fidalgo, 2005). PGE2 is the most abundant prostaglandin in the body and
is the principal bioactive prostaglandin in the GI. PGE2 and PGI2 inhibit gastric acid secretions
when produced by the COX-1 pathway (Nishio, Terashima, Nakashima, Aihara, & Takeuchi,
2007; Wallace, 2008). However, PGE2 has dual effects on gastric secretions and can also
stimulate acid output depending on the specific prostaglandin receptor to which it binds (Kato,
Aihara, Yoshii, & Takeuchi, 2005). Prostaglandins, specifically PGE2, maintain the gastric
mucosal layer by stimulating surface epithelial cells to produce bicarbonate ions and mucus,
which protect the stomach from luminal factors (e.g., low pH stomach acid) damaging the
epithelium, as well as decreasing the permeability of the epithelium (Darling et al., 2004;
Takezono et al., 2004; Wallace, 1989). Reducing the permeability of the epithelial lining of the
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stomach stops gastric acid from penetrating and damaging deeper layers of the stomach,
therefore reducing potential gastric impairment (Takezono et al., 2004).
Inflammation in the stomach can lead to gastric injury. Therefore, reducing inflammation
within the stomach inhibits injury to the stomach itself. Prostaglandins can reduce inflammation
in the stomach by decreasing the release of inflammatory mediators (Wallace, 2008). The
production of PGE2 increases after COX-2 is upregulated in inflammatory conditions
(Samuelsson, Morgenstern, & Jakobsson, 2007) and PGE2 suppresses the immune response by
inhibiting the release of proinflammatory mediators such as interleukin-1 (IL-1) and tumor
necrosis factor α (TNF-α) (Martin & Wallace, 2006; Tang, Libby, Vanhoutte, & Xu, 2012;
Wallace, 2008). On the other hand, reducing levels of PGE2 increases proinflammatory
mediators in the stomach (Musumba, Pritchard, & Pirmohamed, 2009).
Nonsteroidal anti-inflammatory drugs are COX inhibitors
Topical administration of salicylic acid relieves inflammatory pain and can be found in
many plants, those of which have been used for over 3,500 years (Vane & Botting, 1998). In the
19th century, Felix Hoffman chemically acetylated salicylic acid, which came to be known as
aspirin, in order to decrease pain and inflammation associated with rheumatism (i.e.,
inflammation of the joints) (Lanas, 2009). However, patients with rheumatism taking aspirin,
including Hoffman’s father, found that the drug severely irritated their stomachs (Lanas, 2009).
In the early 1970’s, John Vane discovered that aspirin inhibited COX, which subsequently
decreased prostaglandin synthesis (Lanas, 2009; Martin & Wallace, 2006; Vane, 1971). Vane’s
finding created a paradigm shift and led him to win a Nobel Prize in medicine (Lanas, 2009).
After the mechanism of action was discovered, many different types of COX inhibitors were
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then synthesized, which are called nonsteroidal anti-inflammatory drugs (NSAIDs) (Lanas,
2009).
As mentioned above, NSAIDs are the most commonly used pharmaceutical therapies for
pain (Lanas, 2009) and are especially useful in the treatment of inflammatory pain. NSAIDs
decrease pain and inflammation by inhibiting both COX-1 and COX-2 enzyme activity (Figure
2), and subsequently blocking the production of prostaglandins (Rouzer & Marnett, 2009).
Specifically, NSAIDs reduce levels of PGE2 and PGI2 (Crowe et al., 2015; Hecken et al., 2000;
Musumba et al., 2009; Takeuchi, 2012; Wallace, 2013), which are involved in pain and
vasodilation. Although inhibiting COX-1 has acute anti-inflammatory effects throughout the
body, it also paradoxically causes GI irritation by altering the regulatory properties of
prostaglandins. This alteration in prostaglandin levels can cause gastric tissue damage by
hindering gastric epithelial cell renewal and delaying healing of the injury (Musumba et al.,
2009). Conversely, administration of PGE2 blocks the formation of gastric hemorrhages, which
further supports the protective role of prostaglandins in the stomach. Unfortunately, although the
addition of exogenous prostaglandins can be beneficial to gastric health, prostaglandin treatments
are generally not well tolerated by patients. Thus, only 2% of NSAIDs users are co-prescribed
synthetic prostaglandins due to the need to take multiple doses a day as well as adverse side
effects including diarrhea and abdominal pain (Laine et al., 2008; Rostom et al., 2011).
Due to the negative side effects of COX-1 inhibition by NSAIDs, coxibs were developed
approximately 15 years ago. Coxibs are highly selective COX-2 isozyme inhibitors that
circumvent the NSAID-induced gastrointestinal side effects by not inhibiting COX-1 (FitzGerald
& Patrono, 2001). Although coxibs effectively reduced pain and inflammation without GI side
effects (FitzGerald & Patrono, 2001; Laine et al., 1999; Patrono & Baigent, 2009), in humans,
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coxibs significantly increase the risk of major vascular complications, especially heart attacks
(Patrono & Baigent, 2009). Given the controversy sparked by coxibs, essentially swapping the
risk of gastric side effects for increased risk of cardiovascular events, it is not surprising that the
enthusiasm for coxibs has weakened.
NSAID-induced gastric damage
NSAID administration can cause gastric hemorrhages (Figure 3; panel 2), which are
found in the mucosal layer of the stomach (Laine et al., 2008). In the stomach, NSAID-induced
hemorrhages are generally located in the antrum and corpus topographical areas of the stomach,
and rarely occur in the fundus (Kamada et al., 2006; Takeuchi, Ueki, & Okabe, 1986; Trevethick
et al., 1994). NSAIDs not only cause gastric ulcers but also impair the healing of ulcers as they
form.
NSAIDs damage the GI tract through multiple causes, which are generally grouped as
either topical or systemic factors (Schubert, 2008). The most characterized effects include the
inhibition of COX enzymes, which leads to topical epithelial irritation, thus activating
proinflammatory mediators; increasing stomach contractions; and increasing gastric acid
secretion (Figure 4) (Granger & Kubes, 1994; Wallace, 2001; Wallace, Keenan, & Granger,
1990). Considering prostaglandins play a protective role in the stomach, their inhibition leaves
the gastric mucosa vulnerable to gastric damage. While a vulnerable mucosa does not necessarily
result in gastric hemorrhages, the increased gastric secretions overwhelm the already susceptible
mucosa, thereby causing ulcers (Wallace, 2001). Although many factors can contribute to
gastropathy, gastric acid may be a major pathway of ulcer formation, as detailed below.
The many layers of the gastric mucosa (detailed above) defend the gastric epithelium
against damage by gastric acid and topical irritants (Wallace, 2008). However, epithelial cells
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can trap NSAID molecules intracellularly, leading to irritation and damage (Bastaki & Wallace,
1999; Laine et al., 2008). NSAID-induced irritation also increases the epithelial permeability of
the gastric mucosa, thereby impairing the defensive barrier against gastric acid (Brand et al.,
1999). Therefore, NSAID administration can cause a cascade of events by deteriorating the
protective barrier, thereby allowing luminal factors such as gastric acid and the NSAID itself to
penetrate the protective barriers, increasing the chance of hemorrhage.
After the initial irritation, the damage to the epithelial cells recruits and activates white
blood cells, including mast cells, macrophages, and neutrophils (Wallace, 2008). Neutrophils are
the most abundant white blood cells that respond early in the innate immune response, and their
infiltration contributes directly to gastric tissue damage. Myeloperoxidase (MPO) is an enzyme
that is found within circulating neutrophils and is used to indirectly quantify neutrophil activity
in tissue (Liu et al., 1998). Neutrophils and other activated white blood cells release
proinflammatory cytokines, such as TNF-α and interleukin-1β (IL-1β) to the site of the injury
(Wallace, 2008). The resulting heightened immune response to these prototypical,
proinflammatory cytokines causes further mucosal damage and inflammation. Conversely,
blocking the activity of these proinflammatory cytokines attenuates gastric inflammation
(Appleyard, McCafferty, Tigley, Swain, & Wallace, 1996; Wallace, 2008). For example, NSAID
administration significantly elevates plasma levels of TNF-α (Appleyard et al., 1996). However,
deactivating TNF-α by administering anti-TNF-α antibodies prevented NSAID-induced gastric
hemorrhages from forming in rats (Appleyard et al., 1996). These data suggest that inflammatory
cytokines are an important mediator in NSAID-induced gastropathy.
Gastric motility, or stomach contractions, is another pathogenic factor in gastric
hemorrhage development. NSAID administration increases gastric motility, which means there is
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increased muscle contractions (Takeuchi, 2012; Takeuchi et al., 1986). As the muscles contract,
the mucosa folds are compressed and cause the stomach to empty faster (Di Marzo et al., 2008;
Takeuchi, 2012). The disturbance in the mucosal folds due to the mechanical compressions of
the stomach may promote gastric hemorrhage development (Takeuchi, 2012; Yano, Akahane, &
Harada, 1978), because the mucosal ridges are exposed to gastric acid and may be less protected
by a relatively thin coating of mucus and bicarbonate. The NSAID indomethacin increases
gastric motility at ulcerogenic doses in rats (Mersereau & Hinchey, 1982; Takeuchi et al., 1986;
Tanaka, Araki, Komoike, Hase, & Takeuchi, 2001). The effects of NSAIDs on gastric motility
are modulated by the prostaglandin PGE2 (Tanaka et al., 2002). For example, a selective COX-2
inhibitor, rofecoxib, did not change basal motility, whereas a COX-1 inhibitor produced
hypermotility (Tanaka et al., 2001), indicating that NSAID-induced increases in gastric motility
are COX-1 mediated.
Despite increased inflammation and mucosal contractions, damage to the gastric mucosa
does not always progress to the expression of overt gastric hemorrhages because of multiple
mucosal defense mechanisms. One important defense is the process of tissue restitution, or the
migration of healthy cells to the injury site (Wallace, 2001). However, this protective process is
impaired when the wound is exposed to excessive gastric acid secretions. NSAIDs augment
gastric acid secretions, increasing the acidity of gastric pH, which leads to an interruption in
stomach homeostasis (Playford & Ghosh, 2005). The dysregulation of homeostasis caused by
NSAIDs decreases tissue restitution and exacerbates mucosal damage, allowing for further ulcer
development (Wallace, 2001). Therefore, it is plausible that suppression of gastric acid is
critically essential to decreasing the incidence of NSAID-induced ulcers (Wallace, 2001).
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The endocannabinoid system
Cannabis and its main component, Δ9-tetrahydrocannabinol (THC), have been studied in
the gut and, to a lesser extent, gastric maladies in humans and nonhuman animal models. In a
human study of gastric acid secretions, heavy Cannabis users, characterized by smoking
Cannabis more than twice a week, had lower gastric acid secretions than light or non-users
(Nalin et al., 1978). THC also protects the stomach against the development of gastric ulcers in
multiple experimental animal models. For example, in rats, THC inhibited the hemorrhagic
effect of pylorus ligation, in which the lower portion of the stomach is surgically tied off to
prevent it from draining properly, thereby allowing stomach acid to accumulate (Sofia,
Diamantis, Harrison, & Melton, 1978). THC also strongly inhibits NSAID-induced gastric
hemorrhages in mice (Kinsey et al., 2011; Kinsey & Cole, 2013). After mice were administered a
cannabinoid receptor subtype 1 (CB1) antagonist, rimonabant, the gastroprotective effect of THC
was blocked (Kinsey et al., 2011; Kinsey & Cole, 2013). Importantly, the cannabinoid receptor
subtype 2 (CB2) selective antagonist SR144528 had no effect, indicating that THC proffers
gastroprotection through a CB1 receptor-mediated mechanism of action. These data from human
and experimental animal studies suggest that Cannabis may not only mediate gastric acid
production, but that its main component, THC, provides a likely mechanism of gastroprotection.
Although THC has been used for thousands of years and has gastroprotective effects,
unwanted behavioral and cognitive effects such as attention, memory, and motor deficits have
dampened enthusiasm for its clinical use (Kogan & Mechoulam, 2007). Due to these unwanted
side effects of THC, researchers have targeted the endogenous cannabinoid (endocannabinoid;
eCB) system. The endocannabinoid system comprises two receptors (i.e., CB1 and CB2), their
endocannabinoid ligands, and the synthetic/catabolic enzymes that regulate endocannabinoids in
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vivo. The two endogenous cannabinoids, N-arachidonylethanolamine (anandamide) and 2arachidonylglycerol (2-AG), bind to and activate both cannabinoid receptors (Ahn, McKinney,
& Cravatt, 2008). The most abundant endogenous CB receptor ligand is 2-AG, which is
produced on demand and immediately released (Ahn et al., 2008), in contrast to “traditional”
neurotransmitters, which are stored in vesicles. Diacylglycerol lipase α and β (DAGLα and
DAGLβ) synthesize 2-AG, and inhibition of the DAGL enzymes blocks the production of 2-AG,
consequently reducing 2-AG levels (Bisogno et al., 2003; Silvestri & Di Marzo, 2013).
Conversely, 2-AG is broken down by the catabolic enzyme monoacylglycerol lipase (MAGL),
which breaks down 2-AG into arachidonic acid and glycerol, thereby decreasing pools of 2-AG
available to bind to the cannabinoid receptors (Ahn et al., 2008). MAGL is abundant in brain
tissue but can also be found in the muscular and mucosal layers of the gastrointestinal tract
(Blankman, Simon, & Cravatt, 2007; Duncan et al., 2008; Izzo & Sharkey, 2010). Due to rapid
degradation of 2-AG by MAGL, in vivo, genetic deletion or pharmacological inhibition of
MAGL is used to indirectly increase levels of 2-AG (Kinsey et al., 2009; Long, Li, et al., 2009).
In other words, blocking MAGL from degrading 2-AG allows 2-AG to activate the cannabinoid
receptors. Because genetic manipulation is not feasible in humans, current research manipulating
2-AG typically explores the therapeutic efficacy of pharmacologically inhibiting MAGL.
JZL184 is a highly characterized pre-clinical MAGL inhibitor that increases levels of 2AG in the brain and stomach and blocks the development of NSAID-induced gastropathy
(Figure 3; panel 3) (Kinsey et al., 2011; Long, Nomura, & Cravatt, 2009). JZL184 reduces pain
and inflammation by inhibiting the breakdown of 2-AG, thus allowing 2-AG to bind to CB
receptors (Crowe et al., 2015; Ghosh et al., 2013; J. Guindon, Guijarro, Piomelli, & Hohmann,
2011; Kinsey et al., 2009). JZL184 can also induce-CB1 dependent “THC-like” effects such as
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analgesia and decreased locomotor activity (Long, Nomura, et al., 2009). JZL184 inhibits >90%
of MAGL with an irreversible covalent bond, meaning JZL184 binds to MAGL and permanently
alters the chemical structure of the enzyme, subsequently inactivating the enzyme (Long,
Nomura, et al., 2009). Physiological activity of MAGL returns by “turn over” once the enzyme is
reproduced. The permanent, irreversible bond between drug and enzyme leads to a long duration
of action and reduces the frequency of dosing a drug, which is clinically attractive (Singh, Petter,
Baillie, & Whitty, 2011). However, an irreversible drug is also associated with a higher
incidence of side effects (Cisneros et al., 2012; Tuccinardi et al., 2014).
Although JZL184 does not have overt toxicity effects (Nomura et al., 2010), using high
doses of JZL184 can have unwanted side effects. Repeated administration of high dose JZL184
(i.e., 40 mg/kg) reduces CB1 function and expression, which leads to functional antagonism of
CB1 receptors (Schlosburg et al., 2010). In other words, chronic JZL184 administration reverses
the anti-inflammation and antinociception properties of MAGL inhibition. While acute
administration of JZL184 does not have off-target effects with other enzymes, repeated
administration of high dose JZL184 can increase levels of anandamide, which is not catabolized
by MAGL, suggesting that JZL184 can react with other enzymes besides MAGL (Schlosburg et
al., 2010). A first-generation MAGL inhibitor with limited selectivity, URB602, interacts with
multiple other enzymatic targets (Vandevoorde et al., 2007). Given its lack of specificity,
URB602 inhibits COX-2 in vitro (Dong, Lu, Zou, & Yang, 2015), which may indicate MAGL
inhibition affects COX signaling. However, there is no evidence to suggest JZL184 interacts
with the COX enzymes (Long, Li, et al., 2009; Long, Nomura, et al., 2009). Although chronic
high dose JZL184 results in tolerance, lower doses still reduce pain, inflammation, and NSAIDinduced ulcers without negative side effects (Kinsey et al., 2013).
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Endocannabinoids in the gastrointestinal system
While there are some conflicting reports on the specific locations of the DAGL isozymes
(Bashashati et al., 2015), DAGLα is thought to be expressed on enteric nerves and surface
epithelial cells in the GI (Bashashati et al., 2015; DiPatrizio, 2016) and DAGLβ is thought to be
expressed on nerves in the myenteric plexus (Marquez et al., 2009). The presence of DAGL
indicates bioavailability of 2-AG in the gastrointestinal system. For example, data from multiple
labs, including my own data (Ignatowska-Jankowska et al., 2014; Kinsey et al., 2011, 2013;
Nomura et al., 2011) indicate that inhibiting MAGL, thus increasing levels of 2-AG, blocks the
formation of NSAID-induced ulcers (Figure 3), and requires CB1 receptors to block ulcer
formation. MAGL inhibition does not block hemorrhage formation by increasing levels of
prostaglandins in the stomach (Kinsey et al., 2011). Thus, JZL184 may have an effect on other
pathogenic mechanisms of gastric hemorrhages. The following studies were designed to test the
efficacy of the endocannabinoid system in the potential pathways in which NSAID-induced
gastric hemorrhages develop, including gastric inflammation, motility, and acid secretion, as
detailed below.
CB1 receptors are highly expressed throughout the stomach in humans and rodents, with
the highest expression in the myenteric and submucosal plexuses and are co-localized with preand postganglionic cholinergic neurons, which respond to and release acetylcholine (Adami et
al., 2002; Coruzzi et al., 2006; Izzo, Mascolo, & Capasso, 2001; Izzo & Sharkey, 2010). The
neurons innervate the smooth muscle in the myenteric plexus, gastric mucosa, blood vessels in
the submucosal plexus, and on vagal terminals innervating the walls of the stomach (Adami et
al., 2002; Burdyga et al., 2004; Maccarrone et al., 2015; Pazos et al., 2008). Specifically, CB1
receptors are found on intrinsic sensory neurons, interneurons, and excitatory motor neurons
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(Anavi-Goffer & Coutts, 2003; Aviello et al., 2008). Activation of CB1 receptors inhibits
excitation and therefore reduces acetylcholine release (Aviello et al., 2008), which is generally
considered to be the main site of action of cannabinoid effects in the GI.
Due to their inhibition of excitatory neurotransmission, cannabinoids are known to
decrease motility in the gastrointestinal system in humans and other animals (Abalo, Vera,
Lopez-Perez, Martnez-Villaluenga, & Martin-Fontelles, 2012; Aviello et al., 2008; Izzo,
Mascolo, Borrelli, & Capasso, 1999; McCallum et al., 1999), including intestinal transit and
stomach emptying (Di Marzo et al., 2008; Pinto et al., 2002). The cannabinoid-mediated
decrease in motility was blocked after administration of the CB1 antagonist, rimonabant, or
following ablation of the vagus nerve (Krowicki, Moerschbaecher, Winsauer, Digavalli, &
Hornby, 1999; Landi et al., 2002), indicating CB1 receptors facilitate this effect and suggests a
potential CNS involvement.
As detailed above, blocking proinflammatory activity decreases gastric inflammation,
potentially reducing hemorrhage. Cannabinoid receptor agonists block the NSAID-induced
production of proinflammatory cytokines, such as TNF-α and IL-1β (Kinsey et al., 2011; Klein,
2005), suggesting that inhibiting proinflammatory cytokines is a gastroprotective mechanism of
the endocannabinoid system. The current project sought to evaluate the role of MAGL inhibition
on inflammatory mediators, such as cytokines and chemokines, in the mouse stomach using
JZL184, and to extend these findings by examining the effects of JZL184 on MPO activity in the
stomach.
CB1 receptors are expressed on human parietal cells in the gastric mucosa (Pazos et al.,
2008). Parietal cells within the stomach secrete hydrochloric acid to facilitate digestion and
absorption; however, the acid secretions can overpower mucosal defenses if not regulated
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(Schubert, 2008). Parietal cells are located in the oxyntic gland and are stimulated by
acetylcholine, histamine, or the hormone gastrin to increase acid output (Schubert & Peura,
2008). Therefore, histamine and the gastrin analog, pentagastrin, are used experimentally to
induce gastric acid secretions (i.e., secretagogue) in both animals (Gyires et al., 2014; Martinez
et al., 1998; Shujaa et al., 2009) and humans (Rodriguez-Stanley, Redinger, & Miner, 2006).
Exogenous synthetic cannabinoid administration blocks gastric ulcer formation and suppresses
gastric acid secretion in pentagastrin- and histamine-stimulated animal models. These
gastroprotective effects are reversed by CB1 antagonism, suggesting that functioning CB1
receptors are required for the endocannabinoid system to be gastroprotective (Adami et al., 2002;
Coruzzi et al., 2006; Coruzzi, Adami, Coppelli, Frati, & Soldani, 1999; Pazos et al., 2008).
Increased gastric acid output may be one of the primary mechanisms through which NSAIDs are
thought to induce gastric ulcers, but it is unknown whether MAGL inhibition modulates gastric
secretions. Therefore, the study examined the effect of MAGL inhibition on gastric acid output
(Figure 4).
Despite their well-known gastrointestinal side effects, NSAIDs remain the most popular
analgesic class. There are many potential pathways through which NSAIDs, like diclofenac
sodium, cause gastric hemorrhages, including topical and systemic mechanisms. However, the
specific mechanism(s) are not entirely understood. Recently, cannabinoids have been found to
block the ulcerogenic effects of high-dose NSAID administration in mice. Therefore, the overall
goals of the current study were to evaluate the mechanisms of diclofenac-induced gastric
hemorrhages, as well as the gastroprotective mechanisms through which the MAGL inhibitor,
JZL184, prevents the physiological events leading to diclofenac-induced gastropathy. Due to the
breadth of pathogenic mechanisms, the current study evaluated the most characterized
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components of gastric hemorrhages, which include changes in inflammation of the gastric
epithelium, gastric acid secretions, and gastric motility (Figure 4). Although all published
reports in this area have used male mice, exclusively, NSAIDs are used by both sexes, and it is
therefore critically important to establish the NSAID-induced gastric hemorrhage model, as well
as its attenuation by MAGL inhibition, in mice.
The ultimate goal of this research is to improve the lives of patients taking NSAIDs by
informing the development of new, cannabinoid-based gastroprotective therapeutics.
Method
Animals
Adult male and female ICR mice (Harlan Laboratories, Indianapolis, IN) approximately 8 weeks
old were used. The outbred ICR mice have genetic differences that are similar in many ways to
human populations (Aldinger, Sokoloff, Rosenberg, Palmer, & Millen, 2009), thus allowing for
more variability and more conservative results than genetically identical strains. Mice were
housed 3-5 in polysofone plastic cages (Allentown, Inc., Allentown, PA) with food and water
offered ad libitum. Mice were housed in a temperature (20-22°C) and humidity (50 ± 5%)
controlled environment on a 12:12 h light cycle. The Animal Care and Use Committee at West
Virginia University approved all experimental protocols (14-1007).
Drugs
The MAGL inhibitor JZL184 and the NSAID diclofenac sodium salt were purchased from
Cayman Chemical (Ann Arbor, MI). The gastric acid secretagogue pentagastrin and the PPI
(antacid) omeprazole were purchased from Sigma Aldrich (St. Louis, MO). All compounds were
dissolved in a vehicle consisting of ethanol, Cremophor (Sigma-Aldrich), and saline in a ratio of
1:1:18 parts, as described previously (Crowe et al., 2015; Kinsey & Cole, 2013). All solutions
were warmed to room temperature and administered intraperitoneally (ip), subcutaneously (sc),
16
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or per oral (po) at a volume of 10 µl/g body mass. Due to the multiple drugs administered to
individual mice at the same time, different routes of administration were chosen to avoid fluid
overload (Turner, Brabb, Pekow, & Vasbinder, 2011). Diclofenac was given orally (po) to stay
consistent with clinical use in that the NSAID comes into contact with the lining of the stomach.
Omeprazole and JZL184 were administered intraperitoneally (ip), which may have similar
pharmacokinetics to oral administration (Turner et al., 2011). With specific regard to diclofenac
and JZL184, oral administration of diclofenac inhibits gastric prostaglandins and intraperitoneal
JZL184 increases gastric 2-AG levels at the doses chosen here (Kinsey et al., 2011), indicating
that both compounds are indeed active via the selected routes of administration. Pentagastrin was
given subcutaneously because this route allows for injecting a relatively large volume into a
small animal, reducing fluid overload.
Induction of gastric hemorrhage
Mice were randomly assigned to treatment groups. Gastric hemorrhages were induced based on
previously published methods (Kinsey et al., 2011; Naidu, Booker, Cravatt, & Lichtman, 2009).
Mice were weighed, then food-deprived for 24 h with free access to water. A wire mesh barrier
was placed on the bottom of each cage to prevent coprophagia (i.e., eating feces), with the goal
of minimizing stomach contents. On the day of the hemorrhage induction, the mice were
weighed, administered diclofenac or vehicle, and returned to the home cage. After 6 h, the mice
were euthanized via CO2 asphyxiation and their stomachs were harvested, photographed, and
snap-frozen in liquid nitrogen. For a subset of mice (diclofenac dose response with MPO
quantification and a separate cohort of mice for the multiplex assay) mucus was isolated by
scraping with a metal spatula and frozen separately from the stomach. Tissues were stored at 80°C until assays were performed.
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Gastric hemorrhage quantification
Gastric hemorrhages were quantified based on previously reported methods (IgnatowskaJankowska et al., 2014; Kinsey et al., 2011). Six hours after diclofenac treatment, stomachs were
harvested, cut along the greater curvature, and rinsed with distilled water. The tissue was then
placed on a lighted stage and photographed, along with a 1-mm reference, using a Canon EOS
Rebel XS digital camera with a Canon 250D close-up lens (Adorama Inc., New York, NY). The
images were pseudo randomized, renamed, and analyzed using Photoshop (Adobe Systems, Inc,
San Jose, CA). The length of each hemorrhage and the reference was each marked with a 1pixel-wide line and compared, such that the total hemorrhage score in millimeters for each
stomach was calculated using the following equation:
pixels of hemorrhages
= Total hemorrhage length
pixels of 1 mm reference

The experimenter scoring gastric hemorrhages was blind to the treatment condition of each
subject.
Biomarker and mediators quantification
Myeloperoxidase (MPO) is an enzyme produced by neutrophils, which are abundant white blood
cells that are early responders of the innate immune system. MPO levels are commonly used to
indirectly quantify neutrophils (Loria, Dato, Graziani, & Biasucci, 2008). Gastric hemorrhages
were induced with diclofenac (0, 11.11, 33.33, or 100 mg/kg), as detailed above, and mucosal
scrapings were isolated, using a metal spatula. Samples were homogenized using a Tissue Tearor
(Bartlesville, OK) in 5 ml phosphate-buffered saline and MPO activity was quantified by
sandwich enzyme-linked immunosorbent assay (sandwich ELISA) per manufacturer's
instructions (R&D Systems, Minneapolis, MN). All samples were run in duplicate.
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In order to determine the effects of diclofenac and MAGL inhibition on gastric inflammation,
levels of the inflammatory mediators IL-1β, TNF-α, IL-6, IL-10, VEGF-A, and MCP-1 were
measured using a Mouse Inflammatory Cytokines Multiplex kit (Meso Scale Diagnostics,
Rockville, MD), per manufacturer's instructions, which measures multiple analytes
simultaneously. In experiments using whole stomach analysis, mice were administered JZL184
(40 mg/kg) or vehicle 2 h prior to gastric hemorrhage induction via diclofenac (100 mg/kg) and
subjected to the gastric hemorrhage protocol, as detailed above. In the subset of experiments
using mucosal scraping samples, mice were administered JZL184 (8 mg/kg) or vehicle 2 h prior
to gastric hemorrhage induction via diclofenac (100 mg/kg) and subjected to the gastric
hemorrhage protocol, as detailed above. On the day of assay, samples were homogenized in 5 ml
phosphate-buffered saline using a Tissue Tearor (Bartlesville, OK). All samples were run in
duplicate.
Whole stomach samples were also evaluated for MPO and IL-6 activity using separate sandwich
ELISAs, per manufacturer's instructions (R&D Systems, Minneapolis, MN). All samples were
run in duplicate.
Gastric acid secretion
Mice were subjected to the gastric hemorrhage procedure, and gastric secretions were collected 6
h after diclofenac administration (i.e., at the same time as hemorrhages were photographed).
For evaluation of basal vs. pentagastrin-stimulated gastric acid secretions, mice were
administered JZL184 (40 mg/kg), omeprazole (positive antacid control), or vehicle 2 h prior to
vehicle (basal condition) or pentagastrin (0.25 mg/kg; stimulated condition). Mice were
euthanized via CO2 asphyxiation 1 h after pentagastrin administration, then gastric secretions
were collected.
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Gastric acid secretions were collected using gastric lavage, as described previously (Martinez et
al., 1998), with minor modifications. After euthanasia, the stomach was clamped at the lower
esophageal sphincter and the pyloric region to block stomach emptying, and 200 µl of normal
saline was injected into the stomach. The stomach was then harvested and its contents were
collected in a test tube. After gastric lavage, the samples were centrifuged for 7 min at 13000g
and the supernatant was aliquoted into a new tube and stored at -80°C until pH analysis. The
stomach fluid was assessed for pH using a pH microelectrode (Thermo Scientific, PerpHecT
ROSS microelectrode 8220BNWP).
It is noteworthy that the current study measured the pH of gastric secretions mixed with saline,
and therefore did not directly measure acid secretion but the amount of acidity in the stomach.
The changes in gastric pH were inferred as changes in gastric secretions. However, gastric acid
secretion is the primary determinant of gastric pH (Fuchs et al., 1991). For simplicity, I will refer
hereafter to the alterations in pH samples as alterations in gastric acid secretion.
Gastric motility
Gastric emptying was performed as described previously (Di Marzo et al., 2008), with minor
modifications. Mice were weighed, placed on a wire barrier, and fasted for 24 h. The mice were
administered JZL184 (40 mg/kg) or vehicle, then 2 h later, diclofenac sodium (100 mg/kg) or
vehicle was administered 1 h before oral administration by gavage of 0.3 ml solution of 0.5
mg/ml Phenolsulfonphthalein (phenol red; Sigma-Aldrich, St. Louis, MO) dissolved in a vehicle
of distilled water and 1.5% volume of Carboxymethylcellulose (CMC). The CMC vehicle is
useful for oral administration because its high viscosity allows for an even suspension of the
phenol red. At 20 min post phenol red administration, the mice were euthanized and the stomach
was quickly clamped at the lower esophageal sphincter and pyloric region. Mice in the baseline
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group were administered phenol red and immediately euthanized. Samples recovered from these
mice were used as a standard baseline (0% emptying). The stomach was then injected with 0.2
ml of Nanopure filtered (Barnstead NANOpure Water Purification System), deionized water, to
aid the removal of its contents. The stomach was removed, opened along the greater curvature,
and its contents were poured into a test tube and the stomach was rinsed with 3.8 ml Nanopure
filtered, deionized water to remove and collect all remaining phenol red from stomach ridges.
Prior to assay, 2 ml of a 1 mol sodium hydroxide (NaOH) solution was added to each tube to
develop the maximum intensity of the phenol red color. The optical density of each sample was
read on a microplate reader (Molecular Devices, Vmax kinetic microplate reader) at 560 nm
wavelength. As the stomach empties, the phenol red exits the stomach. Thus, a saturated color
indicates slower gastric motility, whereas unsaturated color indicates hypermotility. The
percentage of gastric emptying was calculated according to the following formula:

Statistical analysis

100 × �

1 − OD of phenol red at 20 min
�
OD of phenol red at 0 min

Diclofenac dose-response data were analyzed using one-way analysis of variance (ANOVA),
followed by Dunnett’s post hoc comparisons. To evaluate sex differences in gastric hemorrhages,
diclofenac dose-response data were analyzed using a two-way ANOVA with sex and drug
treatment as the independent variables and hemorrhage length or MPO level as the dependent
variable. As a higher body weight may indicate a larger stomach, thus affecting gastric
hemorrhages, analysis of covariance (ANCOVA) was also used to determine the influence of sex
and drug treatment after controlling for body weight. Inflammatory marker assays, gastric acid
secretion with diclofenac, and gastric motility data were analyzed using a two-way ANOVA with
pretreatment (vehicle, JZL184) and drug treatment (vehicle, diclofenac). Gastric acid secretion
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with pentagastrin data were analyzed using a two-way ANOVA with pretreatment (vehicle,
JZL184, omeprazole) and drug treatment (vehicle, pentagastrin). Two-way ANOVAs were
followed by Tukey’s post hoc comparisons. Correlations between gastric hemorrhage length and
MPO or inflammatory mediators were analyzed using the Pearson’s correlation coefficient.
Differences were considered statistically significant if α < .05.
Experimental plan
Experiment 1. The goal of the first experiment was to determine the doses of diclofenac
that induce gastric hemorrhage and to quantify hemorrhages using MPO as an objective
biomarker. Gastric hemorrhage induction was evaluated with varying doses of diclofenac (11.11,
33.33, or 100 mg/kg, po), with another group of mice receiving vehicle, and subjected to the
gastric hemorrhage protocol, as described above. There were 32 male mice and 33 female mice
used for this experiment. Gastric hemorrhages were quantified by photographic analysis and
confirmed by using MPO activity ELISA, as described in the “Biomarker and mediators
quantification” procedure. Gastric hemorrhage length and MPO levels were then correlated.
Experiment 2. The goal of the second experiment was to quantify inflammatory
mediators. 31 male mice and 32 female mice were administered JZL184 (40 mg/kg, ip) or
vehicle 2 h prior to gastric hemorrhage induction via diclofenac (100 mg/kg, po) or vehicle and
subjected to the gastric hemorrhage protocol, as detailed above. The whole stomachs were
evaluated for protein levels of cytokines (IL-1β, TNF-α, IL-6, IL-10, VEGF-A, and MCP-1)
using a multiplex assay and using IL-6 and MPO ELISAs, as described in the “Biomarker and
mediators quantification” procedure.
Using a separate cohort of mice, 39 male mice and 40 female mice were administered JZL184 (8
mg/kg, ip) or vehicle 2 h prior to gastric hemorrhage induction via diclofenac (100 mg/kg, po) or
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vehicle and subjected to the gastric hemorrhage protocol, as detailed above. The mucus scrapings
from the stomach were evaluated for protein levels of cytokines (IL-1β, TNF-α, IL-6, IL-10,
VEGF-A, and MCP-1) using a multiplex assay, as described in the “Biomarker and mediators
quantification” procedure.
Experiment 3. The goal of the third experiment was to determine the efficacy of
endocannabinoid attenuation of NSAID-induced gastric acid secretion. 40 male mice and 40
female mice were subjected to the gastric hemorrhage procedure, with JZL184 (8 mg/kg)
administered 2 h prior to diclofenac (100 mg/kg). Gastric secretions were collected 6 h after
diclofenac administration (i.e., at the same time as hemorrhages were photographed) and
analyzed for pH, as described above in the “Gastric acid secretion” procedure.
For evaluation of basal vs. pentagastrin-stimulated gastric acid secretions, a separate cohort of 48
male mice were administered JZL184 (40 mg/kg), omeprazole (20 mg/kg), or vehicle 2 h prior to
vehicle (basal condition) or pentagastrin (0.25 mg/kg; stimulated condition). Samples were
collected 1 h after pentagastrin administration, then gastric secretions were collected and
analyzed for pH, as described above in the “Gastric acid secretion” procedure.
Experiment 4. The goal of the fourth experiment was to assess the efficacy of
endocannabinoid attenuation of NSAID-induced hypermotility, as described above in the
“Gastric motility” procedure. 32 male mice were subjected to the gastric motility procedure, with
JZL184 (40 mg/kg) administered 2 h prior to diclofenac (100 mg/kg), and phenol red
administration 1 h after diclofenac. Gastric contents were collected 20 min after phenol
administration. Samples were measured for optical density using a plate reader.
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Results
Diclofenac induces gastric hemorrhages and increases MPO activity in both male and
female mice
In both male and female mice, gastric hemorrhages were induced using various doses of
diclofenac (0, 11.11, 33.33, or 100 mg/kg, po), and subjected to the gastric hemorrhage protocol,
as detailed above. Diclofenac sodium caused a significant increase in gastric hemorrhages in
male [F(3, 28) = 10.72, p < .01; Figure 5A] and female [F(3, 29) = 8.45, p < .01; Figure 5C]
mice, compared to vehicle treated mice. Post hoc analyses revealed that diclofenac induced
gastric hemorrhages at doses of ≥33.33 mg/kg in male mice and 100 mg/kg in female mice. Sex
differences of gastric hemorrhage development were also evaluated. There was no interaction
between sex and drug treatment [F(3, 57) = .917, p = .44; data not shown]. There was a main
effect of treatment [F(3, 57) = 18.36, p < .01], such that diclofenac increases gastric hemorrhage
formation. There was a main effect of sex [F(1, 57) = 4.27, p < .05], such that male mice had
increased gastric hemorrhage length. After controlling for body weight, there was no interaction
between sex and drug treatment [F(3, 56) = .89, p = .45]. There was a main effect of drug
treatment [F(3, 56) = 17.87, p < .01], such that diclofenac increases gastric hemorrhage
formation. However, there was not a main effect of sex [F(1, 56) = 2.67, p = .11].
MPO activity, an indirect measure of neutrophils, was quantified by ELISA. Gastric
hemorrhage length was quantified by photographic analysis and correlated with gastric MPO
activity. Diclofenac dose-dependently induced gastric hemorrhages regardless of sex. Diclofenac
significantly increased MPO level in male [F(3, 28) = 3.53, p < .05; Figure 5B] and female [F(3,
29) = 4.19, p < .05; Figure 5D] mice. Post hoc analyses indicated that diclofenac increased MPO
at ≥33.33 mg/kg in male mice and 100 mg/kg in female mice. Sex differences of gastric MPO
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levels were also evaluated. There was no interaction between sex and drug treatment [F(3, 57) =
.95, p = .42; data not shown]. There was a main effect of treatment [F(3, 57) = 6.48, p < .05],
such that diclofenac increases gastric MPO concentration. There was a main effect of sex [F(1,
57) = 5.25, p < .05], such that male mice had higher levels of MPO. After controlling for body
weight, there was no interaction between sex and drug treatment [F(3, 56) = .93, p = .44]. There
was a main effect of drug treatment [F(3, 56) = 6.34, p < .01], such that diclofenac increases
gastric MPO concentration. However, there was not a main effect of sex [F(1, 56) = 3.10, p =
.08].Because neutrophil infiltration contributes directly to gastric tissue damage, MPO could be
used as an objective biomarker for gastric hemorrhage severity. Therefore, a Pearson’s
correlation coefficient was computed to elucidate the relationship between blind-scored total
gastric hemorrhage length and gastric MPO level. There was a positive correlation between
gastric hemorrhage length and gastric MPO level in male [r = 0.37, N = 32, p < .05], but not in
female [r = 0.33, N = 33, p = .059] mice. However, there was one outlier in the male data (33.33
mg/kg treated mouse) and two outliers in the female data (100 mg/kg treated mice), as defined as
a data point more than 2 standard deviations from the mean. With outliers removed, the
correlation between gastric hemorrhage and MPO level remained significant in male mice [r =
0.57, N = 31, p < .01], and there was a significant correlation in female mice [r = 0.54, N = 31, p
< .01], indicating MPO may be used as an objective biomarker for gastric damage.
Diclofenac increases gastric inflammatory mediators differently in male and female mice
To evaluate the effect of JZL184 on inflammatory markers as a mechanism of
gastroprotection, mice were pretreated with JZL184 (40 mg/kg) or vehicle 2 h prior to
administration of diclofenac (100 mg/kg) or vehicle. Whole stomachs were harvested 6 h after
diclofenac administration. In male mice, the interaction of the pretreatment and drug treatment
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was significant [F(1, 27) = 22.69, p < .01; Figure 6A]. There was a main effect of pretreatment,
such that JZL184 pretreatment significantly decreased gastric hemorrhages [F(1, 27) = 27.42, p <
.01]. There was a main effect of drug, such that diclofenac significantly increased gastric
hemorrhage length [F(1, 27) = 26.82, p < .01]. Post hoc analysis revealed that administration of
JZL184 prior to diclofenac significantly decreased ulcer formation (p < .01). In female mice, the
interaction between pretreatment and drug treatment was significant [F(1, 28) = 31.58, p < .01;
Figure 6B]. There was a main effect of pretreatment, such that JZL184 pretreatment
significantly decreased gastric hemorrhages [F(1, 28) = 31.58, p < .01]. There was a main effect
of drug, indicating that diclofenac significantly increased gastric hemorrhage length [F(1, 28) =
49.40, p < .01]. Post hoc analysis revealed that pretreatment of JZL184 prior to diclofenac
significantly reduced gastric hemorrhages (p < .01). Dexamethasone was used as a positive, antiinflammatory control (Nakamura, Murai, & Ogawa, 1996) and has been shown to reduce
inflammation in the stomach (Kinsey et al., 2011). However, gastric hemorrhages for that
experiment were uncharacteristically low (data not shown) and there were no treatment
differences in male [F(1, 14) = .77, p = .40] or female [F(1, 14) = 1.67, p = .22] mice. Therefore,
dexamethasone was not included in the inflammatory marker assays.
Whole stomachs were then assayed for concentration levels of inflammatory markers by
multiplex assay. Tumor necrosis factor-α (TNF-α) is the main mediator for acute inflammation
and recruits neutrophils and monocytes to the injury site. In male mice, the interaction was not
significant [F(1, 27) = 2.35, p = .15; Figure 7A]. However, there was a main effect of drug,
indicating that diclofenac significantly increased TNF-α [F(1, 27) = 7.82, p < .01], whereas there
was no main effect of pretreatment [F(1, 27) = 3.35, p = .08]. In female mice, the interaction was
significant [F(1, 28) = 11.41, p < .01; Figure 8A]. There was a main effect of drug and a main
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effect of pretreatment, such that diclofenac [F(1, 28) = 14.15, p < .01] and JZL184 pretreatment
[F(1, 28) = 14.05, p < .01] significantly increased TNF-α. Post hoc analysis revealed that JZL184
administration prior to diclofenac significantly increased levels of TNF-α (p < .01).
Interleukin-1β (IL-1β) has biological actions very similar to TNF-α, in that it mediates
local inflammation. In male mice, the interaction was not significant [F(1, 27) = .01, p = .94;
Figure 7B]. There was a main effect of drug, indicating that diclofenac significantly increased
IL-1β [F(1, 27) = 11.76, p < .01], whereas there was no main effect of pretreatment was not
significant [F(1, 27) = 1.18, p = .29]. In female mice, the interaction was significant [F(1, 28) =
7.78, p < .01; Figure 8B]. There was a main effect of drug and a main effect of pretreatment,
indicating that diclofenac [F(1, 28) = 14.44, p < .01] and JZL184 pretreatment [F(1, 28) = 15.55,
p < .01] significantly increased IL-1β, respectively. Post hoc analysis revealed that JZL184
administration prior to diclofenac significantly increased levels of IL-1β (p < .01).
Interleukin-6 (IL-6) production is stimulated by IL-1 and TNF-α and contributes to
systemic effects of inflammation. In male mice, the interaction was not significant [F(1, 27) =
1.66, p = .21; Figure 7C]. However, there was a main effect of drug treatment, in that diclofenac
significantly increased IL-6 [F(1, 27) = 13.44, p < .01], whereas pretreatment had no significant
main effect [F(1, 27) = .67, p = .42]. In female mice, the interaction was not significant [F(1, 28)
= 3.09, p = .09; Figure 8C]. However, there was a main effect of drug treatment and a main
effect of pretreatment, indicating that diclofenac [F(1, 28) = 6.77, p < .05] and JZL184
pretreatment [F(1, 28) = 4.49, p < .05] significantly increased IL-6, respectively.
The anti-inflammatory cytokine, interleukin-10 (IL-10) is a negative feedback regulator
for macrophage activity. In male mice, the interaction was not significant [F(1, 27) = .08, p =
.78; Figure 7D]. However, there was a main effect of drug treatment, such that diclofenac
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significantly increased IL-10 in male mice [F(1, 27) = 11.56, p < .01]. There was no main effect
of pretreatment on IL-10 [F(1, 27) = .44, p = .51]. In female mice, the interaction was not
significant [F(1, 28) = 3.76, p = .06; Figure 8D]. However, there was a significant main effect of
drug treatment and a main effect of pretreatment, in that diclofenac [F(1, 28) = 4.97, p < .05] and
JZL184 pretreatment [F(1, 28) = 9.17, p < .01] significantly increased IL-10, respectively.
Vascular endothelial factor A (VEGF-A) is a protein that promotes angiogenesis and
increases vascular permeability. In male mice, the interaction between JZL184 and diclofenac
was not significant [F(1, 27) = 2.17, p = .15; Figure 7E]. However, there was a main effect of
drug treatment, such that diclofenac significantly increased VEGF-A in male mice [F(1, 27) =
6.77, p < .05]. There was no main effect of pretreatment on VEGF-A [F(1, 27) = 3.94, p = .06].
Similarly, in female mice, the interaction was not significant [F(1, 28) = .88, p = .36; Figure
8E]. There was no main effect of drug treatment [F(1, 28) = 3.42, p = .08] or pretreatment [F(1,
28) = 1.00, p = .33] on VEGF-A.
Monocyte Chemoattractant Protein-1 (MCP-1) regulates migration and infiltration of
monocytes and macrophages. In male mice, the interaction between JZL184 and diclofenac was
not significant [F(1, 27) = .30, p = .59; Figure 7F]. However, there was a main effect of drug,
indicating that diclofenac significantly increased MCP-1 [F(1, 27) = 23.63, p < .01]. There was
no effect of pretreatment on MCP-1 [F(1, 27) = .31, p = .58]. In female mice, the interaction was
significant [F(1, 28) = 5.52, p < .05; Figure 8F]. There was a significant main effect of drug and
main effect of pretreatment, indicating that diclofenac [F(1, 28) = 9.16, p < .01] and JZL184
pretreatment [F(1, 28) = 9.87, p < .01] significantly increased MCP-1, respectively. Post hoc
analysis revealed that JZL184 administration prior to diclofenac significantly increased levels of
MCP-1 (p < .01).
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In male mice, gastric hemorrhage length is positively correlated with levels of IL-6 [r =
.62, N = 31, p < .01] and MCP-1 [r = .41, N = 31, p < .05], but there was no correlation between
hemorrhages and IL-1β [r = .35, N = 31, p = .052], TNF-α [r = .05, N = 31, p = .79], IL-10 [r =
.31, N = 31, p = .09], or VEGF-A [r = .08, N = 31, p = .68]. In female mice, none of the
inflammatory markers were significantly correlated with gastric hemorrhages, IL-1β [r = -.10, N
= 32, p = .60], TNF-α [r = -.11, N = 32, p = .54], IL-6 [r = -.01, N = 32, p = .97], IL-10 [r = -.11,
N = 32, p = .54], MCP-1 [r = -.08, N = 32, p = .68], or VEGF-A [r = .15, N = 32, p = .41].
Because of the unexpected results reported above, the same samples used for the
multiplex assay were assayed using separate IL-6 and MPO ELISAs, to confirm the unexpected
IL-6 results and to indirectly quantify neutrophils, respectively. In male mice, there was no
interaction between pretreatment and drug treatment for IL-6 [F(1, 27) = .23, p = .64; Figure
9A]. In contrast to the multiplex data, there was no main effect of drug for IL-6 [F(1, 27) = .18, p
= .67] but now there is a main effect of pretreatment, in that JZL184 significantly decreased IL-6
[F(1, 27) = 6.40, p < .05]. In female mice, there was no interaction between JZL184 and
diclofenac for IL-6 [F(1, 28) = 1.24, p = .28; Figure 9C], there was a main effect of drug
treatment but, opposite to the multiplex data, diclofenac significantly decreased IL-6 levels [F(1,
28) = 5.43, p < .05], whereas there was no main effect of pretreatment had no effect [F(1, 28) =
.01, p = .92]. The IL-6 data from the multiplex and ELISA assay do not correspond with one
another. Therefore, the results are still inconclusive. In male mice, there was an interaction
between diclofenac and JZL184 for MPO [F(1, 27) = 21.40, p < .01; Figure 9B]. There was a
main effect of drug and a main effect of pretreatment, indicating that diclofenac [F(1, 27) =
31.54, p < .01] and JZL184 [F(1, 27) = 7.18, p < .05] significantly increased MPO levels,
respectively. Post hoc analysis revealed that diclofenac by itself and JZL184 with and without
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diclofenac significantly increased MPO levels compared to vehicle. In female mice, there was
not an interaction [F(1, 28) = .28, p < .60; Figure 9D]. There was no main effect of drug
treatment on MPO levels [F(1, 28) = .80, p < .38]. However, there was a main effect of
pretreatment, in that JZL184 significantly increased MPO levels [F(1, 28) = 15.84, p < .01].
In a different cohort of mice, mucus samples were quantified using a multiplex for
inflammatory marker concentration in order to cut down on the potential “noise” of using the full
stomach sample. Mice were pretreated with JZL184 (8 mg/kg) or vehicle 2 h prior to
administration of diclofenac (100 mg/kg) or vehicle. Mucus samples were collected 6 h after
diclofenac administration. There was an interaction of diclofenac and JZL184 in male [F(1, 35) =
8.50, p < .01; Figure 10A] and female [F(1,36) = 5.27, p < .05; Figure 10D] mice. There was a
main effect of drug treatment, such that diclofenac significantly increased gastric hemorrhage in
male [F(1, 35) = 15.33, p < .01] and female [F(1, 36) = 17.74, p < .01] mice. There was a main
effect of pretreatment, such that JZL184 decreased gastric hemorrhages in male [F(1, 35) = 8.50,
p < .01] and female [F(1, 36) = 5.27, p < .05] mice. Post hoc analyses revealed that JZL184
administration prior to diclofenac significantly decreased gastric hemorrhages in male (p < .01)
and female (p < .05) mice.
Mucus samples were then assayed for concentration levels of inflammatory markers by
multiplex assay. However, all cytokines, except VEGF-A and MCP-1, were below the detection
point for the assay and therefore, not viable for analysis. In male mice, there was no interaction
for VEGF-A [F(1, 35) = 1.74, p = .20; Figure 10B]. There was no main effect of drug treatment
[F(1, 35) = .01, p = .94] or pretreatment [F(1, 35) = .30, p = .59] on VEGF-A. In female mice,
there was no interaction for VEGF-A [F(1, 36) = .32, p = .58; Figure 10E]. There was no main
effect of drug treatment [F(1, 36) = .02, p = .89] or pretreatment [F(1, 36) = 1.3, p = .27] on
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VEGF-A. In male mice, there was no interaction for MCP-1 [F(1, 35) = 1.26, p = .20; Figure
10C]. However, there was a main effect of drug treatment, such that diclofenac significantly
increased levels of MCP-1 [F(1, 35) = 4.44, p < .05]. There was no main effect of pretreatment
on MCP-1 [F(1, 35) = .45, p = .51]. In female mice, there was no interaction for MCP-1 [F(1, 36)
= 3.50, p = .07; Figure 10F]. However, there was a main effect of drug treatment, in that
diclofenac significantly increased levels of MCP-1 [F(1, 36) = 10.87, p < .01]. There was no
main effect of pretreatment on MCP-1 [F(1, 36) = .29, p = .60]. Considering the data was not
detectable using the mucus samples and the inconsistent data, the effects on inflammatory
mediators is still inconclusive.
JZL184 reduces pentagastrin-stimulated gastric acid secretions
The goal of this experiment was to determine the efficacy of endocannabinoid attenuation
of induced gastric acid secretion. Mice were subjected to the gastric hemorrhage procedure, with
JZL184 (8 mg/kg) administered 2 h prior to diclofenac, as described in the Methods. In male
mice, there was a significant interaction between pretreatment and drug treatment [F(1, 34) =
5.51, p < .05; Figure 11A]. However, the post hoc analysis revealed no statistically significant
differences between treatment groups. There were no main effects of pretreatment [F(1, 34) =
0.28, p = 0.60; Figure 11A] or drug treatment [F(1, 34) = 0.57, p = .46; Figure 11A] on acid
secretions. In female mice, there were no main effects of pretreatment [F(1, 34) = 0.03, p = .86;
Figure 11B] or drug treatment [F(1, 34) = 0.16, p = .70] and there was not a significant
interaction [F(1, 34) = 0.52, p = .48] on acid secretions.
The effects of JZL184 on basal and stimulated acid secretions were determined in the
absence or presence of the acid-stimulating drug, pentagastrin, respectively, in male mice. There
was an interaction between pretreatment (JZL184, omeprazole, vehicle) and drug treatment
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(pentagastrin, vehicle) [F(2, 42) = 9.46, p < .01; Figure 12]. There was a main effect of drug,
pentagastrin (0.25 mg/kg) significantly decreased gastric pH [F(1, 42) = 13.18, p < .01],
indicating pentagastrin stimulated gastric acid output. There was a main effect of pretreatment,
JZL184 (40 mg/kg) and omeprazole (20 mg/kg) pretreatments significantly increased gastric pH
[F(2, 42) = 21.07, p < .01], which indicates that both drugs decreased gastric acid output. Post
hoc analysis revealed JZL184 (p < .05) and omeprazole (p < .01) significantly decreased
pentagastrin-stimulated gastric acid secretions and JZL184, but not omeprazole, decreased
unstimulated gastric acid secretions (p < .01).
JZL184 decreases gastric motility
The goal of this experiment was to determine the efficacy of endocannabinoid attenuation
of induced gastric motility. There was an interaction of JZL184 (40 mg/kg) and diclofenac (100
mg/kg) [F(1, 28) = 6.11, p < .05; Figure 13]. There was a main effect of drug treatment and a
main effect of pretreatment, such that diclofenac [F(1, 28) = 6.85, p < .05] and JZL184 [F(1, 28)
= 9.76, p < .01] significantly decreased gastric emptying, respectively. Post hoc analysis revealed
that diclofenac administered prior to vehicle decreased gastric motility (p < .01), which was
unexpected. Similarly, JZL184 decreased gastric motility in the absence (p < .01) and presence
(p < .01) of diclofenac, as compared to controls.
Discussion
The results stated here replicate previous reports that the NSAID, diclofenac sodium,
induces gastric hemorrhages, whereas the MAGL inhibitor, JZL184, stops the formation of these
hemorrhages. The current study expanded the investigation by determining that sex does not
modulate these gastric hemorrhages when controlling for body weight. In addition, the present
data found significant correlations between published hemorrhage quantification methods and
neutrophil levels, as assessed by MPO activity. The current study explored the primary
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mechanisms through which NSAID-induced gastric hemorrhaging is suspected to occur, which
are characterized by topical and systemic mechanisms. Although neither the mechanisms of
NSAID-induced ulcers nor the mechanisms of gastroprotection proffered by MAGL inhibition
are known, there are many potential mechanisms through which gastric hemorrhages are
produced and prevented. Therefore, in the current study, the most characterized potential
mechanisms were evaluated: gastric inflammation, acid secretion, and motility. Although
diclofenac did not increase gastric acid output, JZL184 reduced pentagastrin-stimulated gastric
acid secretion, while also reducing basal secretions. However, MAGL inhibition did not decrease
proinflammatory markers as expected. MAGL inhibition slowed gastric motility, which supports
previous research, but did not further reduce motility when given prior to diclofenac.
Diclofenac dose-dependently increased gastric hemorrhage length and MPO concentration
in both male and female mice. MPO concentration significantly correlated with hemorrhage
length, which indicates MPO may be used as an objective biomarker for gastric damage.
Researchers have used multiple methods to measure gastric hemorrhages, including using a
semi-quantitative clinical scale scoring gastric damage severity (e.g., a 5-point scale with factors
such as ulcer count and redness contributing to a higher score), as well as the objective, visual
quantitative method used in the current study, in which the length of the hemorrhage is measured
compared to a standard. All of the scoring methods presently used may be open to bias even
when blinded, whereas the use of an objective biomarker may increase the reliability and validity
of results. While using MPO as a biomarker of gastric hemorrhage may be helpful to measure
gastric hemorrhages in the lab, MPO is found throughout the body which may hinder its use as a
specific molecular diagnostic for gastric hemorrhages in humans (Loria et al., 2008). Thus,
current diagnostic tools such as endoscopy will likely remain preferred in humans. However, the
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translational potential of the present study is in the manipulation of endocannabinoid levels by
inhibiting MAGL, not measuring a particular marker in gastric biopsies.
Mechanisms of gastric hemorrhage
Diclofenac has previously been shown to increase proinflammatory markers in the stomach
(Kinsey et al., 2011; Wallace, Caliendo, Santagada, Cirino, & Fiorucci, 2007), whereas MAGL
inhibition reduces gastric inflammatory markers (Kinsey et al., 2011). However, the present
study pretreatment of JZL184 prior to diclofenac did not decrease proinflammatory cytokines in
male mice, as previously reported. In female mice, administration of diclofenac, as well as
JZL184, significantly increased proinflammatory cytokines including IL-1β and TNF-α, which
suggests sex differences in the immune response to gastric wounds. JZL184 reduced MCP-1
levels in a pathological state in the colon (Alhouayek, Lambert, Delzenne, Cani, & Muccioli,
2011). The present data indicate diclofenac increased MCP-1 levels but found no attenuation
with JZL184 administration in male mice. Conversely, JZL184 increased levels of MCP-1 in
female mice when administered prior to diclofenac, which further supports sex differences in
immune response. Because of the surprising results, the same samples were quantified for a
second time using an IL-6 ELISA. However, there were no treatment interactions in male and
female mice in IL-6 levels and the results did not replicate the results found using the multiplex
assay.
In order to reduce the potential cytokine “noise” of the whole stomach assay, mucus
scrapings collected from a separate cohort of mice were also assayed for inflammatory markers.
Considering NSAID-induced gastric hemorrhages form in the mucosal layer, using mucosal
samples potentially allows for a more focused measurement of gastric inflammation.
Unfortunately, all of the assayed cytokines, except VEGF-A and MCP-1, fell below detection

34

ENDOCANNABINOID MODULATION OF GASTROPATHY

range and could not be analyzed. There were no treatment differences of VEGF-A levels in male
or female mice. In male mice, diclofenac significantly increased MCP-1 in the mucus samples,
which corroborates the whole stomach data. In female mice, diclofenac increased MCP-1 in
mucus samples, which differs from the JZL184/diclofenac increase in MCP-1 as shown in the
whole stomach data. Because of the conflicting results of the multiple assays, the effect of
JZL184 on inflammatory markers remains unclear.
As mentioned in the Introduction, NSAIDs not only induce gastric damage but can also
impair the healing of the injury. The present study evaluated the levels of two gastroprotective
cytokines, IL-10 and VEGF-A, which may promote healing of gastric lesions. IL-10 is produced
by monocytes and is an anti-inflammatory cytokine that suppresses pro-inflammatory cytokine
release (De Waal Malefyt, Abrams, Bennett, Figdor, & Vries, 1991; Roncarolo et al., 2006).
VEGF-A is important in the immune response because it stimulates new blood vessel growth,
which fosters healing (Salgado et al., 2001; Takahashi, 2011; Wallace, 2008). In the present
study, neither VEGF-A nor IL-10 levels were reduced after diclofenac administration, indicating
that a reduction in these signaling molecules may not be a main contributor to diclofenacinduced ulcers. However, pretreatment with JZL184 increased IL-10 levels in female mice,
which may suggest MAGL inhibition stimulates healing of NSAID-induced gastric damage by
increasing levels of IL-10. However, IL-10 increases after proinflammatory cytokine elevation
(Figure 14), so it is still unclear if JZL184 exerts its gastroprotection through anti-inflammatory
mediators without first determining the proinflammatory cytokine signaling in the samples.
Cytokines are dynamic signaling proteins that work in concert with one another, interacting
in a complex network that can alter immune cell signaling and function. A multiplex
immunoassay is a strong tool for quantifying multiple cytokines in a small sample, with the goal
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of getting a better picture of the response of a whole network of inflammatory cells (BurgosRamos, Martos-Moreno, Argente, & Barrios, 2012; Kingsmore, 2006). However, it is difficult to
fully understand the context of the cytokine levels when looking at one time point, as was chosen
for the design of the present study. Therefore, an important follow-up study would include
multiple time points for evaluating cytokine levels. Such a design would help elucidate whether
the cytokine and chemokine levels we observed are actively rising or declining. Considering
immune cells, such as monocytes, macrophages, neutrophils, and T cells, secrete many different
cytokines, another possible future direction would be to use fluorescence-activated cell sorting
(FACS; flow cytometry) or immunohistochemistry to determine the different immune cell
populations involved in the response to NSAID-induced gastric hemorrhage. Another interesting
follow-up would be to potentially isolate and culture gastric neutrophils and macrophages from
diclofenac-treated mice and stimulate the cells, in vitro, with JZL184 to determine which
cytokines are synthesized. Delineating the changes in cell populations at the injury site might
provide more insight into the immune response, as well as the sex differences in cytokine levels
reported above.
Although many advances have been made in biomedical research, a major shortcoming of
preclinical research is the overreliance on male subjects and the assumption that data from male
mice will generalize to all humans. This shortcoming has received a fair amount of recent
scrutiny and is reflected in the new NIH guidelines, which urge including both sexes in research.
Published reports in gastrointestinal research have used male mice, exclusively; therefore, the
current study used both male and female mice and analyzed data. The difference between the
sexes reported here emphasizes the importance of using both sexes in research. Although there
were no sex differences observed in the ulcerogenic effects of diclofenac after controlling for
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body weight (i.e., no effect of sex on gastric hemorrhage length), there were sex differences in
the immune response to NSAID-induced gastric damage. The sex effects may be due to a
difference in immune response to the injury. Estrogens and prolactin, which are hormones more
predominant in female mice, can be stimulated by cytokines to increase cellular (i.e., cytokines)
and humoral (i.e., antibody production) immune reactions (Bouman, Jan Heineman, & Faas,
2005; Cai et al., 2016; Orbach & Shoenfeld, 2007), which may account for the higher incidence
of autoimmune disorders in females (Cai et al., 2016). Because these hormones elicit a more
vigorous inflammatory response in females, cutaneous wounds heal faster in women, whereas
testosterone, the primary male sex hormone, mainly suppresses macrophage function, which
corresponds to delayed wound healing in men (Cai et al., 2016; Darnall & Suarez, 2009). Gastric
samples from female mice reported here had higher concentrations of the proinflammatory
cytokines tested, which may be a result of hormone-stimulated immune response. In other words,
the elevated proinflammatory cytokines levels in female mice may stimulate gastric hemorrhage
healing more so than male mice (Figure 14). A potential follow-up study would determine the
effects of specific hormones on gastric inflammation caused by diclofenac. For example, given
the substantial data that estrogens and prolactin modulate immune function, using
ovariectomized female mice and administering specific exogenous hormones may provide
further understanding into the altered immune response to gastric inflammation.
An increase in gastric acid secretion is thought to be a main pathogenic mechanism of
NSAID-induced gastric hemorrhages (Wallace, 2008). However, assessing gastric acid levels
was particularly more challenging than originally proposed in the current study. The goal of
measuring gastric acid was to assess acid secretions continuously over a 4 h period. During this
time, a secretagogue, such as pentagastrin or diclofenac, would be administered to increase
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gastric acid output, and then the addition of JZL184 would elucidate the role of MAGL
inhibition in gastric acid alterations. The main issues with the procedure were that the many
anesthetics we tried worked either too well or not well enough (thus no data collection occurred)
and that blood pooled near the pyloric sphincter where the stomach contents were collected (thus
contaminating the baseline samples). Although the surgical techniques and anesthetic issues
improved after consulting with the Clinical Veterinarian, the veterinary technicians, and an
expert in small animal surgery, the other main issues of the procedure continued unimpeded.
Therefore, stomach contents were collected at one time point (i.e., gastric lavage procedure) to
determine the effect of JZL184 on gastric secretions, in place of a continuous measurement of
gastric secretions.
NSAIDs in vivo increase baseline and stimulated gastric acid secretion, and support the idea
that gastric acid is involved with ulcer formation (Salvatella et al., 2004). However, there are
conflicting reports on whether diclofenac itself alters acid secretions. Diclofenac decreased pH
and increased total acidity, as compared to vehicle treated rats (Khan & Khan, 2013). However,
other reports did not find treatment differences between diclofenac- and vehicle-treated rats
(Reuter, Davies, & Wallace, 1997). Conversely, diclofenac significantly decreased basal- and
stimulated-gastric acid output in isolated rabbit gastric glands, whereas aspirin and indomethacin
increased stimulated acid output (Salvatella et al., 2004), which suggests that specific NSAIDs
may have different modulatory effects on gastric acid secretion. In the current study, diclofenac
did not increase gastric acid secretions, indicating diclofenac may cause hemorrhage formation
through a nonacidic mechanism. These conflicting reports underscore differences across species,
collection methods, as well as differences of in vitro and in vivo contexts (Devi et al., 2007;
Reuter et al., 1997; Rodriguez-Stanley et al., 2006; Salvatella et al., 2004). Still, acute
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administration the of NSAID naproxen did not change basal or stimulated levels of pH in
humans, but decreased the total volume of gastric fluid released, ultimately increasing acid
concentration (Rodriguez-Stanley et al., 2006). It is plausible that diclofenac works through a
similar mechanism to increase acid concentration in humans that we were unable to capture in
mice because of differences related to species or methodology.
In the present study, JZL184 significantly decreased gastric acid secretion (i.e., JZL184
increased pH of stomach contents) in both basal and pentagastrin-stimulated conditions 1 h after
pentagastrin administration. However, JZL184 did not alter gastric acid in the absence or
presence of diclofenac following the “Induction of Gastric Hemorrhage” procedure outlined in
the Methods. The different pretreatment times of JZL184 administration prior to euthanasia in
the gastric acid collections (1 h when using pentagastrin compared to 6 h when using diclofenac)
suggest that JZL184 may initially decrease acid secretions within the first few hours after
administration. As with the cytokine study, a follow-up study may focus on evaluating the effects
of MAGL inhibition at multiple time points. Currently, it remains unclear whether diclofenac
alters gastric acid output. However, JZL184 does reduce acid early on, and it is plausible that
MAGL inhibition proffers gastroprotection through an antacid mechanism.
In addition to gastric acid secretions, one of the primary, suspected mechanisms through
which NSAIDs cause gastric hemorrhages is by increasing mechanical compressions of the
stomach (i.e., increasing gastric motility) (Takeuchi, 2012; Wallace, 2008). Considering that
cannabinoids reduce gastrointestinal motility in animals, including humans (Esfandyari et al.,
2006; Izzo & Sharkey, 2010; Maccarrone et al., 2015; McCallum et al., 1999), we hypothesized
that JZL184 would attenuate NSAID-induced increases in stomach contractions. As
hypothesized, JZL184 decreased gastric motility in the current study, whereas diclofenac,
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contrary to expectations, slowed gastric motility. JZL184 did not further reduce the gastric
emptying of diclofenac, suggesting that the gastroprotection of MAGL inhibition does not occur
through gastric motility changes.
In previous reports, gastric motility was increased using a different NSAID, indomethacin.
Hypermotility is cause by the inhibition of COX-1 and while diclofenac inhibits both COX-1 and
COX-2, it is more selective for COX-2, whereas indomethacin is more selective for COX-1
(Patrono & Baigent, 2009). The difference in COX selectivity may alter which mechanisms
significantly contribute to pathophysiology (Rodriguez-Stanley et al., 2006; Smecuol et al.,
2001). A future direction may be to evaluate indomethacin in the gastric motility protocol used
here. In addition, motility is generally assessed in rats (as opposed to mice used here) and is
quantified by inserting a balloon into the stomach and recording changes in pressure to determine
gastric contractions (Mersereau & Hinchey, 1982; Takeuchi et al., 1986; Tanaka et al., 2001).
The gastric motility assay used in the current study focused more on overall function and may
not be sensitive enough to see alterations in stomach contractions caused by diclofenac. For
example, measuring pressure changes using balloon manometry in the stomach may reveal a
more subtle mucosal compression than can be determined in whole stomach movement, as
measured by gastric emptying in the present study.
Alternative mechanisms of gastric hemorrhage
Due to the numerous possible mechanisms that may be involved in the formation of
NSAID-induced ulcers, not all of the potential pathways were examined in the current study. A
proposed pathway that was not evaluated here is deficient wound healing, caused by NSAIDinduced hindering of microcirculation of the gastric mucosa (Ma et al., 2001; Wallace, 2008).
Specifically, COX inhibition is proposed to alter neutrophil activation and gastrointestinal
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permeability, thereby increasing ulceration (Reuter et al., 1997; Rodriguez-Stanley et al., 2006).
The present data indicate that diclofenac dose-dependently increases MPO, indirectly suggesting
that diclofenac increases neutrophil infiltration into the stomach. In other words, as compared to
controls, the stomachs of mice treated with diclofenac had more neutrophil activation.
An alternative model involving neutrophils relates less to their proinflammatory effects than
on their physical interaction with capillaries. Neutrophils are thought to contribute to NSAIDinduced gastric damage by adhering to the vascular endothelium, thereby inhibiting the ability of
capillaries to maintain normal blood flow to the mucosa (by physically blocking the movement
of red blood cells), and by producing oxygen-derived free radicals, which cause tissue damage
(Beck et al., 2000; Wallace & Vong, 2008). Through the activation of neutrophils, NSAIDs
foster oxygen metabolite free radical synthesis and also decrease the antioxidizing enzymes that
defend against reactive oxygen metabolites (Pohle et al., 2001), thus further increasing free
radical activity. Free radicals cause oxidative degradation of lipids, which damages endothelial
cells, subsequently forming gaps in the cell membrane (Beck et al., 2000; Kwiecien, Brzozowski,
& Konturek, 2002). The free radical induced damage increases permeability of the stomach
barrier, which reduces the protective lining of the gastrointestinal system (Kwiecien et al., 2002;
Pohle et al., 2001). NSAIDs dose-dependently increase extravasation in the intestines (Beck et
al., 2000; Reuter et al., 1997), indicating the intestinal barrier is compromised after
administration. Using mice with genetically reduced free radical production, but having normal
neutrophil adhesion properties, showed a significant decrease in barrier permeability and
indomethacin-induced gastric hemorrhages (Beck et al., 2000). Protection against barrier
deficiency and hemorrhagic effects of the mutant mice indicate the neutrophil-dependent release
of oxides may play a bigger role in hemorrhage formation than neutrophil adhesion to the
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endothelium itself. Thus, a potential future direction would be to evaluate MAGL inhibition on
free radical production.
Another pathway of NSAID-induced microcirculation disruption could be due to inhibition
of platelet function. Aggregation of platelets causes clotting and therefore acts as a “brake” for
bleeding, which is critically important for wound reparation (Wallace, 2008). Platelets can also
be protective because VEGF-A is mainly concentrated in platelets, which promotes blood vessel
growth. The prevention of platelet function and aggregation can decrease VEGF while also
increasing bleeding at the injury site (Ma et al., 2001), thereby contributing to the risk of death in
chronic NSAID users (Sung et al., 2010). Platelet accumulation is stimulated by thromboxane,
which is produced by COX-1 (Wallace, 2008). COX-2 inhibition does not affect platelets, which
may explain why COX-2 selective inhibition is not associated with gastropathy (Wallace, 2008).
Following COX-1 inhibition by NSAIDs, thromboxane is decreased and platelet function is
subsequently reduced (Smith, Garavito, & Dewitt, 1996; Wallace, 2013). Increasing
thromboxane levels stimulates gastric healing (Ma et al., 2001), suggesting that thromboxane is
important for wound reparation. Cleavage of 2-AG via MAGL leads to an increase in free
arachidonic acid, which activates platelets in vitro (Brantl, Khandoga, & Siess, 2014). However,
inhibiting MAGL (for example, with JZL184) blocks the catabolism of 2-AG into arachidonic
acid, and this drop in arachidonic acid reduces platelet aggregation (Brantl et al., 2014). Thus,
increased platelet accumulation is most likely not the gastroprotective mechanism of MAGL
inhibition.
While the current study focused on MAGL inhibition, experiments from our lab
(Ignatowska-Jankowska et al., 2014; Kinsey et al., 2011; Kinsey & Cole, 2013), and others
(Gyires et al., 2014; Izzo et al., 2001; Sasso et al., 2012) indicate that inhibiting the catabolic

42

ENDOCANNABINOID MODULATION OF GASTROPATHY

enzyme fatty acid amide hydrolase (FAAH), which then increases levels of the endocannabinoid
anandamide, blocks the formation of NSAID-induced ulcers through a CB1 mechanism of action.
Administration of anandamide directly into the brain prevents gastric hemorrhage formation
(Shujaa et al., 2009). Surprisingly, the peripherally restricted FAAH inhibitor (i.e., inhibiting
FAAH in peripheral tissues only), URB937, also blocks gastric hemorrhages (Sasso et al., 2012).
Thus, there are discrepancies between possible central and peripheral, as well as neural and nonneural mechanisms. Therefore, a possible future direction would be to evaluate the central and
peripheral effects of the endocannabinoid system’s involvement in NSAID-induced gastropathy.
Using mice genetically deficient in FAAH either globally, which have ubiquitously elevated
anandamide levels [i.e., FAAH(-/-)], or mice expressing FAAH in neural tissue only, which have
elevated anandamide levels only in non-neural tissue (i.e., stomach) [i.e., FAAH-NS], as well as
wild-type control mice [i.e., FAAH (+/+)] would provide a powerful tool for determining the
necessity of peripheral nerves in FAAH blockade of gastric inflammation. We would anticipate a
decrease in gastric hemorrhages in FAAH (-/-) mice, which have elevated anandamide levels and
have been shown to attenuate ulcerogenesis (Naidu et al., 2009), but not in FAAH-NS mice,
which have elevated anandamide levels only in non-neural tissues, indicating that a nervousdependent mechanism is responsible for endocannabinoid-mediated gastroprotection.
Cannabinoids in GI disorders
In addition to reducing gastric hemorrhages, cannabinoids may be beneficial for other
gastrointestinal system disorders. Work from my lab has shown that preclinical use of THC is
gastroprotective (Kinsey & Cole, 2013), and there is substantial evidence that cannabinoids
attenuate GI disorders in humans, highlighting the translational potential of cannabinoids in the
gut. For example, due to its anti-nausea and appetite stimulating effects, a synthetic, oral
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preparation of THC, dronabinol, is currently approved by the Food and Drug Administration for
the treatment of chronic wasting conditions (Sticht, Rock, Limebeer, & Parker, 2015). There is
also evidence indicating elevated endocannabinoid levels may be involved in reducing nausea in
patients (Sticht et al., 2015). The anesthetic, propofol, indirectly increased levels of the
endocannabinoid, anandamide, and is associated with a reduction in post-operative nausea in
patients (Kumar, Stendall, Mistry, Gurusamy, & Walker, 2014; Sticht et al., 2015).
Endocannabinoid levels are also implicated in motion-induced nausea. For example, people
experiencing motion-sickness had lower blood levels of anandamide and 2-AG, indicating that
higher levels of endocannabinoids may be protective against motion sickness (Choukèr et al.,
2010). Conversely, the CB1 receptor selective antagonist, rimonabant, increased nausea in
humans (Van Gaal, Pi-Sunyer, Despres, McCarthy, & Scheen, 2008), indicating CB1 mediates
the anti-nausea effects of cannabinoids.
In addition to gastric disorders, cannabinoids are also active in the gut. For example,
inflammatory bowel disease (IBD) encompasses the many forms of chronic inflammation in the
gastrointestinal system, such as colitis and Crohn’s disease. IBDs cause severe abdominal pain,
diarrhea, reduced appetite, and weight loss. Patients with IBD report self-medicating with
cannabis in order to relieve these symptoms (Lal et al., 2011). Cannabis use is more likely for
individuals within this patient population if there is also a history of chronic analgesic use, which
indicates that, at least for some individuals, traditional analgesic are not effective for reducing
disease-related pain (Lal et al., 2011). Patients with colitis who used cannabis reported a
decrease in diarrhea, most likely stemming from cannabinoid-mediated gastrointestinal
hypomotility (Naftali, Mechulam, Lev, & Konikoff, 2014). A small placebo-controlled clinical
trial indicated that THC reduced disease-related pain and increased quality of life in patients with

44

ENDOCANNABINOID MODULATION OF GASTROPATHY

Crohn’s disease (Naftali et al., 2013). Endocannabinoids have also been implicated in IBD.
Levels of anandamide are significantly reduced in biopsies of human IBD-inflamed intestine (Di
Sabatino et al., 2011). The decrease in anandamide was caused by both an increase in
degradation and a decrease in synthesis of the endocannabinoid (Di Sabatino et al., 2011), either
of which may alter IBD-related increased intestinal motility. Similarly, prevention of the
breakdown of anandamide reduces disease-induced inflammation in a mouse model of colitis
(Massa et al., 2004). In a pre-clinical study, IBD increased endotoxins in the blood, intestinal
barrier permeability, and inflammation in mice (Alhouayek et al., 2011). Repeated
administration of JZL184 (which increases 2-AG levels) normalized IBD mice in disease scores,
histology, and inflammation, reduced endotoxins, repaired intestinal barrier permeability, and
restored mucosal structure (Alhouayek et al., 2011). Pharmacological blockade of either CB1 or
CB2 reversed the effects of JZL184, indicating activation of both receptors mediates the
reduction of IBD symptoms (Alhouayek et al., 2011).
The highest expression of the 2-AG producing enzyme, DAGL, in the periphery is found in
the stomach and colon (Bashashati et al., 2015; DiPatrizio, 2016). Considering 2-AG slows
motility by decreasing acetylcholine release on enteric nerves, using DAGL inhibitors, thus
decreasing 2-AG levels, increases motility during pathological state with no basal changes
(Bashashati et al., 2015). Therefore, DAGL inhibitors could be a novel therapeutic target for
constipation.

Parallel wound healing and pain models
One limitation of the current study is the acute model of gastric wound healing, in that
NSAID-induced ulcers are usually fully healed within 24 h of NSAID administration (data not
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shown). However, the risk of death from gastric hemorrhage increases with duration of a
perforated ulcer over 24 h, which is particularly germane for elderly patients (Kocer et al., 2007).
Therefore, I also assessed eCB modulation in a different model of chronic wound healing.
Chronic stress significantly impairs wound healing in humans and other animals. For example,
people experiencing chronic psychological stress, such as Alzheimer’s Disease caretakers, have
slower skin biopsy wound healing than "non-stressed" controls (Head, Farrow, Sheridan, &
Padgett, 2006; Kiecolt-Glaser, Marucha, Mercado, Malarkey, & Glaser, 1995). Similarly,
restraint stress prolongs cutaneous wound healing and induces gastric hemorrhages in mice and
other rodents (Liu et al., 1998; Padgett, Marucha, & Sheridan, 1998). A delay in wound closure
is undesirable because open wounds increase exposure to microorganisms, and heighten the risk
of secondary insult and infection (Padgett et al., 1998). Similar to gastric hemorrhages, one
strategy to increase cutaneous wound healing rate is to attenuate inflammation during the wound
healing process (Head et al., 2006; Padgett et al., 1998). Cannabinoids attenuate stress effects
(Carrier, Patel, & Hillard, 2005), have anti-inflammatory properties (Ghosh et al., 2013; Klein,
2005), and enhance in vitro wound healing (Wright et al., 2005). Therefore, the goal of my study
was to determine the efficacy of inhibiting MAGL or FAAH to normalize in vivo cutaneous
wound healing in mice subjected to repeated restraint stress. Restraint stress significantly delayed
cutaneous wound healing, but either manipulation of the endocannabinoid system had no effect
on wound closure (data not shown). Thus, the extensive psychological stress induced by restraint
may be too advanced for endocannabinoids to overcome in order to rectify wound healing.
Furthermore, in vitro effects of cannabinoids on “wound healing” may be model specific and not
predictive of in vivo effects.
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As outlined in the Introduction, chronic high dose JZL184 administration reverses the antiinflammatory and antinociceptive properties of MAGL inhibition, which is most likely due to the
irreversible alterations to MAGL. Conversely, reversible enzyme inhibitors have fewer
deleterious side effects than irreversible inhibitors (Cisneros et al., 2012; Tuccinardi et al., 2014).
In collaboration with a pharmaceutical company, I recently evaluated a novel reversible MAGL
inhibitor in an NSAID-model of gastric hemorrhage. Acute administration of the experimental
MAGL inhibitor significantly attenuated neuropathic pain in mice. In addition, acute and chronic
administration of the reversible MAGL inhibitor blocked the development of NSAID-induced
gastric hemorrhages, indicating that the reversible MAGL inhibitor does not undergo tolerance
(Crowe, Pink, Peluso, & Kinsey, in prep). An interesting future direction would be to evaluate
the reversible MAGL inhibitor on the pathogenic mechanisms of NSAID-induced ulcers reported
in the current study. While the compound is not yet commercially available, this is an exciting
new class of MAGL inhibitors.
NSAIDs are used worldwide, especially in chronic pain patients. Thus, decreasing doses of
NSAIDs concomitantly reduces the risk of side effects, and therefore may be beneficial to the
population. One strategy for reducing drug doses is by combining drugs with different
mechanisms of action, to produce greater pain attenuation than individually administered
analgesics (Raffa, 2001). Patients taking high doses of an analgesic, who have a higher risk of
experiencing negative side effects, could potentially take two drugs in lower doses, thereby
decreasing the potential for side effects. Thus, a dual administration approach may allow for
subclinical dose of each drug, lessening the side effects of each compound while maintaining
adequate pain relief (Josée Guindon, Walczak, & Beaulieu, 2007). Work from my lab (Grim et
al., 2014; Naidu et al., 2009), and others (Sasso et al., 2012; Scarpelli, Sasso, & Piomelli, 2015),
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has shown that targeting separate systems (i.e., endocannabinoid degradative enzymes and
cyclooxygenases) potentiates analgesia. Expanding on these studies, I recently published that
combined inhibition of MAGL and COX enzymes synergistically reduced neuropathic pain in
mice (Crowe et al., 2015). In other words, the combined inhibition of MAGL (i.e., using
JZL184) and COX (i.e., using diclofenac) enzymes may be beneficial in maximizing analgesia
while at the same time reducing NSAID side effects, in particular gastrointestinal ulcers.
Interestingly, taken with the results of the current study, even if high doses of NSAIDs are used,
pretreatment with a MAGL inhibitor will block NSAID-induced gastric hemorrhages. While this
is an exciting outcome, MAGL inhibitors are not currently approved for use in humans, and thus
clinical trials are still needed to test the efficacy of these drugs.
Research limitations
The aims of the current research were to evaluate multiple possible pathomechanisms of
NSAID-induced gastric hemorrhages. However, there were some limitations of the study.
Patients are prescribed NSAIDs for persistent pain and inflammation and will therefore, use
NSAIDs repeatedly. However, the model used in the present study is an acute model of NSAID
administration, unlike the chronic use of NSAIDs found in clinical settings. While acute use of
NSAIDs does induce gastric damage, the chronic inhibition of COX-1 and COX-2 from repeated
NSAID use can increase the incidence of severe, life-threatening gastric hemorrhages. Therefore,
a potential future direction may be to evaluate gastric hemorrhages after chronic administration
of an NSAID.
While one strength of this study is the evaluation of cytokine signaling in both male and
female mice, it is difficult to fully understand the circumstance of the cytokine levels when
looking at one time point, as was selected for the design of the present study. Therefore, a
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potential follow-up study would include evaluating cytokine levels at multiple time points, which
would provide a more complete understanding of the relationship between the cytokines
analyzed for the present study.
Gastric pH fluctuates throughout the day and can be affected by food intake, water
consumption, and time of day. Therefore, the optimal method to evaluate drug-induced changes
in pH would be to continuously sample gastric contents over an extended period of time in order
to limit any environmental- and time-dependent influences on gastric secretions. However, this
methodology was not able to be accomplished for the current study. Therefore, a potential
follow-up study might use separate cohorts of mice to evaluate gastric contents at multiple time
points to fully elucidate the time course of gastric pH changes due to MAGL inhibition.
NSAIDs have been shown to increase the frequency of stomach contractions, as assessed
by pressure changes in the stomach. The gastric motility assay used in the current study focused
more on overall stomach emptying function and may not be sensitive enough to investigate
alterations of stomach contractions caused by diclofenac. For example, measuring pressure
changes using balloon manometry in the stomach may reveal a more subtle change in mucosal
compression than can be determined in whole stomach functioning, as measured by gastric
emptying in the present study.
Conclusion
Diclofenac dose-dependently increases gastric hemorrhages in male and female mice,
whereas inhibiting the degradation of the endocannabinoid, 2-AG, attenuates NSAID-induced
gastric hemorrhage. Three main pathogenic mechanisms, gastric acid, inflammation, and
motility, were evaluated to better understand the formation and prevention of gastric
hemorrhages. The first potential ulcerogenic mechanism evaluated was gastric inflammation.
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Diclofenac dose-dependently increased neutrophil infiltration in both male and female mice,
indicating that diclofenac induces a cell-mediated inflammatory response. However, JZL184 did
not attenuate cytokine and chemokine levels in male or female mice, as hypothesized. Multiple
assays were run to further determine inflammatory cytokine signaling in gastric inflammation,
however, the results were contradictory and inconclusive. Future studies may focus on cytokine
involvement at multiple time points in gastric hemorrhage development and prevention. The
second aim of the study was to assess the effects of JZL184 on basal and diclofenac- or
pentagastrin-stimulated gastric acid. Neither JZL184 nor diclofenac produced any changes on
gastric acid secretions. However, in the pentagastrin-stimulated acid model, JZL184 decreased
gastric acid secretions in both basal and stimulated conditions, indicating that JZL184 may be
gastroprotective through a transient antisecretory mechanism. Another potential mechanism
evaluated in the present study was mechanical compressions of the stomach, or gastric motility.
As hypothesized, JZL184 decreased gastric motility, although diclofenac also slowed gastric
motility, indicating that diclofenac-induced ulcers most likely do not occur through increased
gastric motility, at least not as measured functionally, as in the present study. In light of the
present data, NSAIDs are most likely causing gastric hemorrhages through multiple pathways
simultaneously. In other words, one potential pathomechanism of NSAID-induced hemorrhages
by itself will not likely result in gastric hemorrhages, but it is the combined physiological
changes that is prompting ulcer development. Although the gastroprotective mechanisms of
JZL184 remain unclear, the present data support the idea that MAGL is a promising target to
protect against NSAID-induced gastric hemorrhages in male and female mice.
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Figure 1. Schematic diagram of stomach organization topographical areas and
anatomy. The stomach is subdivided into four layers: mucosa, submucosa, muscularis
propria, and serosa. The mucosa layer of the stomach is lined with epithelial cells,
which are folded into gastric pits that give the stomach its characteristic “ridged”
appearance. Layers of the stomach contain blood vessels, connective tissue, and
muscle.
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Figure 2. Simplified schematic of the MAGL inhibitor JZL184 blocking diclofenacinduced gastric pathology. JZL184 inhibits monoacylglycerol (MAGL), which
catabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG) into arachidonic acid
(AA) and glycerol. Thus, JZL184 increases brain, spinal cord, and stomach levels of 2AG, in vivo. Diclofenac inhibits cyclooxygenases (COX), thereby decreasing
prostaglandin synthesis from arachidonic acid, and inducing gastric inflammation and
ulceration.
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Figure 3. Representative images of mouse stomachs. Mice were food deprived for 24 h
and then administered diclofenac sodium (100 mg/kg, po) or vehicle. Gastric hemorrhages
were induced by diclofenac (center), whereas the MAGL inhibitor JZL184 (right)
prevented diclofenac-induced hemorrhage formation.
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Figure 4. Schematic of potential pathogenesis mechanisms of NSAID-induced gastric
hemorrhaging, as evaluated in the current study. The most characterized pathways of
NSAID gastropathy are inflammation of the stomach lining, increased gastric acid
secretion, and hypermotility. (Adapted from Wallace, 2008)

67

ENDOCANNABINOID MODULATION OF GASTROPATHY

Figure 5. Diclofenac increased gastric hemorrhages and MPO levels. Mice were fasted for
24 h, administered diclofenac (100 mg/kg, po) or vehicle, and stomachs were harvested
and mucus collected 6 h later. In mucus samples, diclofenac dose-dependently increases
gastric hemorrhage length and gastric mucus myeloperoxidase (MPO) levels in male (n =
8) (A, B) and female (n = 8-9) (C, D) mice. Data presented as mean ± SEM; *p < 0.05 vs.
vehicle; ** p < 0.01 vs. vehicle
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Figure 6. The MAGL inhibitor JZL184 prevents the development of gastric hemorrhages
induced by diclofenac in male (A) and female (B) mice. Mice were fasted for 22 h,
administered JZL184 (40 mg/kg, ip) or vehicle, then diclofenac (100 mg/kg, po, black bars)
or vehicle (white bars) 2 h later, and stomachs were harvested 6 h later. Data presented as
mean ± SEM (n = 7-8); **p < 0.01 vs. vehicle/vehicle; ## p < 0.01 vs. vehicle/diclofenac
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Figure 7. Diclofenac increases inflammatory cytokines in whole stomach in male mice. Mice
were fasted for 22 h, administered JZL184 (40 mg/kg, ip) or vehicle, diclofenac (100 mg/kg,
po, black bars) or vehicle (po, white bars) 2 h later, and stomachs were harvested 6 h later.
Cytokines and chemokines were analyzed using a multiplex assay. In whole stomach,
diclofenac significantly increases levels of TNF-α (A), IL-1β (B), IL-6 (C), IL-10 (D), VEGFA (E), and MCP-1 (F). JZL184 does not block diclofenac-induced cytokine elevations. Data
presented as mean ± SEM (n = 7-8).
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Figure 8. JZL184 administration prior to diclofenac increases inflammatory cytokines in
whole stomach in female mice. Mice were fasted for 22 h, administered JZL184 (40 mg/kg,
ip) or vehicle, diclofenac (100 mg/kg, po, black bars) or vehicle (po, white bars) 2 h later, and
stomachs were harvested 6 h later. TNF-α (A), IL-1β (B), IL-6 (C), IL-10 (D), VEGF-A (E),
and MCP-1 (F) were analyzed using a multiplex assay. Data presented as mean ± SEM (n =
8); **p < 0.01 vs. vehicle/vehicle
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Figure 9. Diclofenac increases gastric MPO levels. Whole stomachs were assayed for IL-6
and MPO using an enzyme-linked immunosorbent assay (ELISA). In male mice, JZL184 (40
mg/kg ip) significantly decreases IL-6 (A). JZL184 with and without diclofenac increases
levels of MPO (B). In female mice, diclofenac significantly decreases IL-6 (C). JZL184
increases levels of MPO (D). Data presented as mean ± SEM (n = 7-8); **p < 0.01 vs.
vehicle/vehicle
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Figure 10. Diclofenac increases the chemokine MCP-1 in stomach mucus. Mice were fasted
for 22 h, administered JZL184 (8 mg/kg, ip) or vehicle, diclofenac (100 mg/kg, po, black
bars) or vehicle (po, white bars) 2 h later, and stomachs were harvested and mucus collected 6
h later. The MAGL inhibitor JZL184 prevents the development of gastric hemorrhages
induced by diclofenac in male (A) and female (D) mice. Inflammatory markers were analyzed
using a multiplex assay. In mucus samples, only VEGF-A and MCP-1 were detected in the
assay. There were no treatment differences in VEGF-A in male (B) or female (E) mice.
Diclofenac significantly increases MCP-1 in male (C) and female (F) mice. Data presented as
mean ± SEM (n = 9-10). **p < 0.01 vs. vehicle/vehicle; # p < .05, ## p < 0.01 vs.
vehicle/diclofenac
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Figure 11. Gastric secretion acidity is unaffected by JZL184 or diclofenac. Mice were fasted
for 22h, administered JZL184 (8 mg/kg, ip) or vehicle, diclofenac (100 mg/kg, po, black bars)
or vehicle (po, white bars) 2h later, and gastric contents were harvested 6h later. Diclofenac
and JZL184 do not alter gastric acid secretions in either male (A) or female (B) mice. Data
presented as mean ± SEM (n = 10)
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Figure 12. JZL184 increases gastric pH in basal- and stimulated-acid conditions. Mice were
fasted for 22 h, administered JZL184 (40 mg/kg, ip), omeprazole (20 mg/kg, ip) or vehicle
(ip), acid secretion was stimulated 2 h later with pentagastrin (0.25 mg/kg, sc, black bars) or
vehicle (sc, white bars), and gastric contents were collected 1h later. Data presented as mean ±
SEM (n = 8); ** p < .01 vs vehicle/vehicle, # p < .05, ## p < .01 vs vehicle/pentagastrin
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Figure 13. JZL184 and diclofenac decrease gastric emptying. Mice were fasted for 24 h. The
mice were administered JZL184 (40 mg/kg) or vehicle, then 2 h later, diclofenac sodium (100
mg/kg, po, black bars) or vehicle (po, white bars) was administered 1 h before oral
administration by gavage of phenol red (0.5 mg/ml). JZL184 and diclofenac significantly
reduce gastric emptying of phenol red as compared to control mice. Data presented as mean ±
SEM (n = 8); ** p < .01 vs vehicle/vehicle
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Figure 14. Schematic of possible sex differences in immune response. After
mucosal damage, TNF-α, IL-1β, IL-6, and MCP-1 are produced and increase
inflammation at the site of injury (solid line). These proinflammatory cytokines
then stimulate production of the anti-inflammatory cytokine, IL-10, and VEGF-a
(dashed line). In the current data, female mice have higher cytokine activity than
male mice, which may indicate a more vigorous immune response, as depicted by
the cytokine activity peaks, or an earlier cytokine response, as depicted by the
shifted timeline.
77

